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Directed Evolution of Cyclic Peptides for Inhibition of Autophagy
Joshua Gray B.A.
Advisory Professor: Steven Millward, Ph.D.
In recent decades it has become increasingly clear that induction of
autophagy plays an important role in the development of treatment resistance and
dormancy in many cancer types. Chloroquine (CQ) and hydroxychloroquine (HCQ),
two autophagy inhibitors in clinical trials, suffer from poor pharmacokinetics and high
toxicity at therapeutic dosages. This has prompted intense interest in the
development of targeted autophagy inhibitors to re-sensitize disease to treatment
with minimal impact on normal tissue. We utilized Scanning Unnatural Protease
Resistant (SUPR) mRNA display to develop macrocyclic peptides targeting the
autophagy protein LC3. The resulting peptides bound LC3A and LC3B—two
essential components of the autophagosome maturation machinery—with midnanomolar affinities and disrupted protein-protein interactions (PPIs) between LC3
and its binding partners in vitro. LC3-binding SUPR peptides re-sensitized platinumresistant ovarian cancer cells to cisplatin treatment and triggered accumulation of
the adapter protein p62 suggesting decreased autophagic flux through successful
disruption of LC3 PPIs in cell culture. In mouse models of metastatic ovarian cancer,
treatment with LC3-binding SUPR peptides and carboplatin substantially reduced
tumor growth after four weeks of treatment. These results indicate that SUPR
peptide mRNA display can be used to develop cell-penetrating macrocyclic peptides
that target and disrupt the intracellular PPIs that govern the autophagic machinery.
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CHAPTER ONE
INTRODUCTION
Traditional drug design has focused primarily on the development of small
molecules that occupy a specific region of physiochemical parameters of size
(MW<500), hydrogen bond donors (HBD<5), hydrogen bond acceptors (HBA<10)
and lipophilicity (LogP > 5) (1). Commonly known as the “rule of 5” (RO5), these
parameters of “druglikeness” emphasize the pharmacokinetic properties of oral
bioavailability and cell permeability. Targets considered “druggable” (e.g. enzymes)
typically have well-defined surface binding pockets that small molecules are able to
access with high affinity and selectivity to modulate protein function within minutes to
hours following administration. Protein families that inherently modify or interact with
small compounds like G protein coupled receptors, nuclear hormone receptors,
proteases, phosphatases, and kinases have all historically been amenable to
drugging (2). Unfortunately, these easily druggable targets represent a relatively
small fraction of target space. Indeed, it is estimated that only ~10% of the human
proteome is made up of druggable targets and that only half of those represent
useful targets for treating disease (2). As of 2016, only 549 unique human protein
targets have FDA-approved small molecule inhibitors (3).

The overwhelming

majority of disease-related protein activities are considered undruggable as their
critical interactions occur through interfaces of large protein surfaces (750-1500 Å2)
that druglike small molecules simply lack the size to efficiently disrupt (4).
Biologics (e.g. monoclonal antibodies and their variations) have seen
development increase dramatically over the last two decades due to the ability of
9

these large compounds (~5-150 kDa) to inhibit protein-protein interactions (PPIs) by
binding to large surface areas on targets with extremely high affinity and specificity.
This class of compound however is inherently restricted to targeting extracellular
proteins as the size of antibodies prevents them from crossing the cell membrane
and accessing intracellular protein targets.

Although antibodies possess the

requisite affinity and target selectivity for disrupting extracellular PPIs, their high cost
of production and chemical instability complicates their translation from the bench to
the clinic.
Peptides occupy an important intermediate chemical space between small
molecules and biologics that strongly positions them to become powerful therapeutic
inhibitors of intracellular PPIs. With typical sizes between 5-30 AAs (~500-3500 Da),
peptides possess sufficient surface area to achieve antibody-like binding to protein
surfaces and inhibition of PPIs without becoming too large to categorically prohibit
cell uptake. Protein interactions with peptides of 5-10 amino acids typically have a
shared surface area >400 Å2 (5) which is thought to be sufficient for effective
disruption of most PPIs. Historically, peptides have been dismissed as potential drug
candidates due to a number of factors including susceptibility to proteolysis, lack of
inherent cell permeability, and challenging library screening procedures. As we will
see, cyclization and N-methylation of the peptide backbone provide answers to
many of the cell permeability and serum stability issues inherent to using peptides as
drugs against intracellular targets. Combined with recent advances in rapid
screening and directed evolution technologies, cyclic peptides have enormous
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potential to become a preferred molecular scaffold for the inhibition of intracellular
PPIs.
Scanning Unnatural Protease Resistant (SUPR) peptide mRNA display is a
relatively recent advancement of the original mRNA display technology developed
by Roberts and Stzosak that introduces macrocyclization, N-methyl amino acid
incorporation, and protease screening (6). In this manner, libraries of trillions of
unique compounds can be screened to produce cyclic peptide scaffolds that not only
have superb affinity and selectivity for the target protein of interest, but are also
nearly completely resistant to proteolytic degradation.

Cyclization, serves two

purposes in the SUPR peptide architecture. On one level, cyclization serves to
constrain the three dimensional conformation of peptides, potentially freezing them
in an active, target-binding state (7–9). Cyclization has also been shown to increase
resistance to proteolytic degradation, possibly through increased conformational
rigidity (10,11).

The incorporation of N-methyl amino acids has been shown by

many investigators to drive proteolytic stability by introducing tertiary amides in the
backbone (11,12). Indeed, the incorporation of a single N-methyl amino acid has
been shown to provide protection against proteolysis that extends several residues
on either side of the incorporation site (13).
My work is based on the hypothesis that several of the characteristics that
define the SUPR peptide architecture will also impart cell permeability.

In the

following sections, I will lay out some of the principles of cell permeability and the
requisite physicochemical properties required to impart cell permeability to peptides.
I will briefly review the growing field of cell permeable cyclic peptides with particularly
11

emphasis on the features of cell permeability that overlap with those found in SUPR
peptides. I will provide an overview of mRNA Display and SUPR mRNA display as
well as a brief discussion of autophagy and the role of protein-protein interactions in
this process. Finally, I will introduce the LC3 protein, its PPIs, and its role as a target
for SUPR peptide mRNA Display.
Methods by which molecules cross the cell membrane
Cellular plasma membranes are made up of a complex network of
phospholipids arranged in a bilayer which protects the cell from its environment. The
lipids that comprise the cell membrane consist of strongly hydrophilic head group
attached to a hydrophobic lipid chain. These lipids are arranged in a double layer
with the head groups exposed to the cell interior and exterior which isolates the
hydrophobic lipid tails from the aqueous intracellular and extracellular environments
(14). This arrangement creates a superb barrier between the extracellular space and
the cell interior that is impermeable to all but a select few compounds. Internalization
of molecules primarily occurs through three pathways: passive diffusion of
moderately polar small molecules driven by a concentration gradient; endocytosis,
the process of internalizing compounds adhered to the cell surface in vesicles made
up of portions of the cell membrane; and active transport of molecules in a highly
specific manner by ATP-activated protein transporters embedded in the surface of
the cell membrane (15). With the exception of some classes of peptides that are
actively transported, most peptides typically access the cytosol through passive
diffusion or endocytosis. Some small di- and tri-peptides are actively transported by
the proton-coupled oligopeptide transporter (SLC15) family of membrane transport
12

proteins (16,17) and some moderately sized (~8 residues) naturally occurring
bicyclic peptides actively transported by the organic anion transporter polypeptide
(OATP) family of transport proteins (18,19). As we will see, linear peptides lack
many of the features that characterize highly cell permeable compounds. Significant
modification—such as cyclization and incorporation of non-proteogenic amino
acids—is typically required to achieve efficient entry into the cytosol.
Passive Diffusion
Small, moderately polar molecules are among the few classes of compounds
that are able to passively cross the cell membrane in an energy-independent
manner (Figure 1A). Membrane transit from the aqueous environment of the
extracellular space to the aqueous environment of the cytosol occurs in three steps.
The molecule first partitions into the outer hydrophilic membrane surface, then
transits the inner hydrophobic membrane core, and finally exits the inner membrane
surface to access cell interior (20). Passive transport across the cellular membrane
is driven by a concentration gradient across the membrane and therefore—ignoring
any energetic costs of establishing the gradient—is an energy-independent process.
The rate of diffusion across plasma membranes can be modeled simply by the
derivation of Fick’s first law (15):
𝒌𝒌𝒇𝒇 × 𝑺𝑺 × ∆𝑪𝑪(𝒕𝒕)
𝒅𝒅𝒅𝒅
=
𝒅𝒅𝒅𝒅
𝒅𝒅 × 𝑴𝑴𝑴𝑴𝟏𝟏/𝟐𝟐

Where dM/dt is the rate of transfer of compound across the membrane, kf is the
compound’s membrane-water partition coefficient, S describes the surface area of
the membrane, ∆C(t) describes the concentration gradient across the membrane, d
13

describes the thickness of the membrane, and MW1/2 is the square root of the
molecular weight. The MW and kf are the two physical properties of the compound
that define its ability to cross lipid bilayers. The membrane-water partition coefficient
is the ratio of the concentration of a solute in water and and in lipid (such as octanol)
when the two solvents are mixed and it is one measure of compound lipophilicity.
Transit across membranes is directly proportional to kf, therefore strongly lipophilic
compounds should more readily transit the hydrophobic membrane interior.
Additional modeling studies have (20) identified desolvation as a critical aspect to
initiation of partitioning of the membrane and that energy of desolvation strongly
affects rate of transit across the membrane. Effectively this means that more
lipophilic compounds pay a lower desolvation penalty when transitioning into the
membrane interior. Druglike compounds are rarely strongly hydrophobic however,
due to issues of solubility in the aqueous extracellular and intracellular
environments. Successful therapeutic compounds must possess a delicate balance
of hydrophobicity to drive cellular internalizations and hydrophilicity to maintain
solubility. The rate of transfer is also inversely proportional to the MW of the
compound meaning that smaller molecules will more diffuse more readily across cell
membranes than larger molecules. If one plots this equation, it quickly becomes
clear that the contribution of MW to permeability rapidly becomes asymptotic and
above 400 Da the permeability penalties imposed by increasing MW effectively
saturate. At this point, the equation is heavily dominated by kf and ∆C.
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Figure 1: Diffusion and Endocytosis. A) Passive diffusion of molecules across the cell membrane is driven by a
concentration gradient. Small, moderately polar molecules partition the outer membrane, diffuse through the
membrane interior and access the cytosol. B) Endocytotic invagination of the cell membrane expends energy in
the form of ATP to internalize compounds by pinching off portions of the membrane to form internal vesicles that
are trafficked to various cellular compartments.
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When we consider the Rules of 5 (RO5) for “druglike” compounds capable of
passive permeation discussed earlier, it becomes readily apparent that most
peptides—including cyclic peptides—are profoundly non-druglike. The RO5 provide
convenient, easy to remember guidelines that predict whether a compound is likely
to have acceptable passive permeability and oral bioavailability. With an average
molecular weight of approximately 110 Da per amino acid, cyclic peptides begin to
push the size boundaries of druglikeness in as few as five residues. On top of this
fact, each peptide bond contributes 1 hydrogen bond donor (HBD) and 2 hydrogen
bond acceptors (HBAs) before consideration of the chemical composition of the
amino acid side chains. Based on these two factors, the RO5 guidelines predict that
both cyclic and linear peptides containing 5 or more amino acids should not be cell
permeable by passive diffusion.
For the most part this prediction is accurate, though there are notable
exceptions in which cyclic peptides—both naturally occurring and synthetic—readily
diffuse through the cell membrane. A key feature commonly found passively
permeable cyclic peptides is the elimination of backbone HBDs through Nαmethylation of backbone amines and extensive intramolecular hydrogen bonding
(15,21). Hydrogen bonds between backbone amide protons and water typically have
a free energy of around 1 kcal/mol which is imposed as a desolvation penalty that
must be paid when partitioning the membrane (22,23). Incorporation of Nmethylation and intramolecular hydrogen bonds reduces the number of uncapped
polar N-H groups in the peptide backbone that would require desolvation in order to
achieve diffusion into the hydrophobic membrane interior (24). The inclusion of at
16

least one depsipeptide linkage has also been shown to contribute to passive
permeability in a similar manner to N-methylation (21) as the replacement of an
amide group in the peptide backbone with an ester linkage eliminates an HBD.
However, the introduction of ester bonds in the backbone may impair the
translatability of depsipetides into effective clinical therapeutics due to serum stability
issues introduced by susceptibility to ester hydrolysis. Stability studies of cyclic
lipodepsipeptides in human serum revealed that ~65% of lipodepsipeptide was
degraded in 24 hours—primarily due to hydrolysis of the ester bond—compared to
no significant degradation of the control peptide which contained only amide
backbone bonds (25).
Small tetramer and pentamer cyclic peptides and depsipeptides such as
tentoxin and romidepsin largely obey the RO5 size restrictions and also reduce HBD
load through N-methylation, depsipeptide linkages, and intramolecular hydrogen
bonding (21,26,27). The most prominent example of a large cyclic peptide the
passively permeates the cell membrane is Cyclosporine A (CsA), an 11-mer cyclic
peptide immunosuppressant that possesses both excellent oral bioavailability and
cell permeability despite violating the RO5 guidelines on size and HBD/HBAs
(Figure 2A)(28). CsA contains 7 N-methyl amino acids and can undergo a
significant conformational shift to reduce the number of backbone HBDs exposed to
solvent. In aqueous environments, CsA adopts an “open” conformation which allows
its backbone amides to interact with water molecules or its intracellular target,
cyclophilin. When entering the cell membrane, CsA adopts a “closed” conformation
in which all of its backbone amides that are not N-methylated participate in
17

intramolecular hydrogen bonds which dramatically reduces its polar surface area
(29). Interestingly, Cyclosporine E (CsE)—a variant of CsA that lacks N-methylation
of Val11—does not completely deplete HBDs in the peptide backbone and
conformational changes occur at a 10-fold slower rate than CsA. This results in
dramatically reduced cellular permeability and highlights the extent to which
desolvation penalties drive membrane permeability by passive diffusion (29). Other
large cyclic peptides such as enniatin B, patellamide C, and the PF1171 family of
peptides that exhibit strong passive permeability all completely deplete backbone
HBDs through a combination of N-methylation and intramolecular hydrogen bonding
(21,30).
Endocytosis and Macropinocytosis
Endocytosis is the process of internalizing membrane proteins, lipids, and
extracellular molecules from the exterior surface of the cell by invaginating the cell
membrane and forming an internal vesicle (Figure 1B)(31). Once internalized the
vesicle is transported to intracellular compartments (i.e. lysosomal or golgi
compartments) for downstream processing. While clathrin-mediated endocytosis has
been studied extensively in the literature (32), other mechanisms of receptormediated endocytic uptake that do not rely on clathrin remain fairly poorly
understood.

18

Macropinocyt
osis represents one
of the more wellstudied forms of nonclathrin-mediated
endocytosis.

Unlike

endocytosis

which

proceeds

through

invagination of the
membrane,
micropinocytosis
involves
formation
Figure 2: Examples of various constrained cyclic peptides. A) Cyclosporine
A, a naturally occurring 11mer peptide contains 7 N-methylated backbone
residues (red) and can undergo a conformational shift, forming extensively
internal hydrogen bonds in the peptide backbone allowing it to passively diffuse
through the hydrophobic membrane interior. B) An example SUPR peptide
produced by a selection against HER2 (Fiacco 2016). SUPR peptide mRNA
display produces cyclic peptides that combine both N-methylation (red) and
macrocyclization through a hydrophobic crosslinker (blue) which may impart
intrinsic cell permeability. C) Example stapled peptide ATSP-7342, this peptide
utilizes a hydrophobic crosslinker to enforce α-helical structure. ATSP-7342
efficiently accesses the cytosol through endocytosis and inhibits MDM2/MDMX
PPIs. The presence of a hydrocarbon staple appears to be critical for cell
permeability. A modified version of this stapled peptide (ALRN-6924) is currently
in Phase-II clinical trials for the treatment of several types of cancer.

the
of

large

vesicles through the
actin-mediated
extension
membrane
called

of
folds
ruffles

outwards from the

cell surface (33,34). Activation of membrane growth factor receptors such as EGFR
is known to initiate membrane ruffling and, as a consequence, highly elevated
macropinocytic activity is often observed in cancer cells that overexpress growth
factor receptors (35). Macropinocytosis is non-selective in its cargo uptake and its
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vesicles are typically much larger than other endosomal vesicles. Despite this,
macropinocytotic vesicles undergo very similar processing through the endosomal
and lysosomal compartments (36).
Both receptor-mediated endocytosis and macropinocytosis are subjects of
interest as tools for delivering exogenous compounds to the cell interior, particularly
in the case of large molecules and nanomaterials that cannot access the cell interior
through passive diffusion or active transport (37). Macropinocytosis in particular has
been studied extensively as a mechanism to deliver therapeutics semi-specifically to
cancer cells, due to the tendency of these cells to be highly macropinocytotic by
virtue of growth factor receptor overexpression (36). It is currently believed that
cytosolic access following endosomal or macropinocytotic uptake is limited primarily
by escape from the endosome interior rather than initial uptake efficiency.
The discovery in the early 1990s of two peptides—the transactivator of
transcription domain of HIV (TAT, GRKKRRQRRRPQ) and Antennapedia
homeodomain of Drosophila (penetratin, RQIKIWFQNRRMKWKK)—which were
found to cross the cell membrane through endocytic uptake initiated the study of socalled cell-penetrating peptides (CPPs)(38,39). This class of heavily cationic and
amphipathic peptides are readily taken up into the cell by endocytosis and
subsequently escape the endosomal vesicles to access the cytosolic milieu. As of
early 2020, more than 1700 unique peptide sequences have been classified as
CPPs according to CPPsite 2.0, a database that tracks CPPs in the literature (40).
While the exact mechanisms by which CPPs access the cytosol remains a topic of
debate, it is consensus agreement that internalization of CPPs occurs through
20

endosomal uptake initiated by association with the outer plasma membrane.
Cationic CPPs such as TAT and polyarginine depend on coulombic interactions
between the positively charged side-chains of basic amino acids—primarily arginine
and lysine—and the negatively charged surfaces of cellular membrane (41,42). It
has also been established that the association of the guanidinium sidechains of
arginine with heparan sulfate drives initiation of endocytosis, providing evidence that
CPPs are active initiators of endocytosis. Uptake of these peptides by endocytosis
may also benefit from normal membrane recycling activities (43,44). Like cationic
CPPs such as TAT, amphipathic peptides such as penetratin and RW9
(RRWWRRWRR) form hydrogen bond associations with the surface of the outer cell
membrane but also undergo hydrophobic interactions via sequestration of aromatic
side-chain residues into the lipid bilayer (45,46).
Following internalization of the endosome, CPPs must escape from the
endosomal-lysosomal compartment. While it is has been established that CPPs do
escape endosomes, escape efficiency for linear CPPs is generally very poor and the
vast majority of linear CPPs remain trapped in the endosome and are eventually
degraded without ever gaining access to the cytosol (15). Proposed mechanisms of
escape have been poorly studied until very recently and evidence supporting
hypothesized mechanisms of endosomal escape remains sparse. One of the more
prominent theories of endosomal escape posits that the CPP associates with the
interior surface of the endosome as it matures and acidifies, generating transient
toroidal or barrel stave pores in the membrane through which the CPP escapes by
diffusion into the cytosol (47,48). However, this model cannot fully explain why some
21

CPPs are able to facilitate the transport of large macromolecules (e.g. nucleic acids
and nanoparticles) out of endosomes (49,50).
Until very recently, CPP research has focused nearly entirely on linear
peptides. According to CPPSite 2.0, a database that tracks the CPP literature, nearly
95% of unique CPP sequences are linear peptides (40). The uptake efficiency of
linear CPPs—defined as the concentration of peptide in the cytosol versus the
extracellular concentration—ranges from 0.2-4.0%. This low rate of uptake is
thought to be driven largely by poor endosomal escape rather than by inefficient
endosomal loading (51). Cyclic CPPs, on the other hand, have demonstrated the
potential for significantly higher uptake efficiencies—in some cases more than two
orders of magnitude higher—than those observed in linear CPPs. Studies of cyclized
variants of TAT, polyarginine, amphipathic polarginine peptides incorporating
tryptophan groups, and many other cyclic CPPs have demonstrated several-fold
higher uptake rates in cyclic variants of the peptide compared to linear formulations
(52–54). The Pei group has designed a family of amphipathic, cyclic nona-peptides
combining two aromatic, hydrophobic residues (phenylalanine, 2-naphthylalanine)
and four arginine residues that have achieved cytosolic delivery efficiencies between
20-120%—as much as 2 orders of magnitude greater than linear TAT—and show
evidence of delivering large macromolecules and fluorescent proteins to the cytosol
with similar efficiency (55–57). Interestingly these molecules appear to escape from
early endosomes rather than late endosomes as TAT most other linear CPPs do.
The combination of conformational stabilization through macrocyclization and
amphipathicity seem to be critical physiochemical features that drive efficient access
22

to the cytosol by CPPs. A potential explanation for this phenomenon may be that the
bottleneck for cytosolic access lies in endosomal escape rather than initial
endosomal uptake; traditional cationic CPPs like TAT appear to have similar initial
endosomal uptake to cyclic, amphipathic CPPs despite dramatically lower cytosolic
access efficiencies (15). It has been proposed that pore formation in endosomes
requires association with the inner endosomal membrane by cationic guanidinium
groups and simultaneous, orthogonal insertion of hydrophobic side chains into the
membrane (57). The enhanced backbone rigidity enforced by macrocyclization or
hydrocarbon stapling may reduce conformational entropy and cause amphipathic
cyclic peptides to more consistently adopt conformations capable of achieving both
hydrophilic and hydrophobic interactions with the endosomal membrane than linear,
cationic and amphipathic CPPs can achieve. This implies that the conformational
restrictions required for endosomal release may be different from those required for
target engagement. Thus, CPPs are perhaps best employed as cell delivery vectors
rather than as a component of a target-binding scaffold.
While eminently useful for basic research and chemical biology applications,
the highly cationic nature of CPPs has proved a sizeable hurdle to their translation
into clinical use. In vivo biodistribution studies of common CPPs like TAT, penetratin,
and polyarginine reveal that these compounds initially bind strongly to the
vasculature local to the site of administration followed by rapid clearance through the
liver. In some cases, 90% liver uptake was observed in as little as 30 minutes
(58,59). This rapid accumulation of compound in the liver is known to be associated
with acute liver toxicity at clinically relevant doses (58). Despite these issues that
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impair the ability to translate CPPs into clinical use, they have contributed
expansively to the understanding of how to design therapeutic peptides with
enhanced cell permeability.
There is evidence that stapled peptides—a special class of cyclic peptides in
which the side chains of the i, i+4 or i, i+7 residues are crosslinked with a
hydrocarbon linker to enhance α-helical structure and increase protease
resistance—are cell permeable at least in part through endosomal uptake and
escape. Hydrocarbon stapling typically occurs between the i,i+4 or i,i+7 residues
because these spacings correspond to one or two α-helical turns respectively (60).
Bridging the side-chains at these positions with a hydrophobic crosslinker
significantly reinforces the α-helical structure of the macromolecule. An exhaustive
study by Verdine and colleagues on the uptake mechanisms of over 200
hydrocarbon stapled peptides and CPPs found that cell permeability was correlated
with formal positive charge and that cellular uptake was abrogated in CHO cells
deficient in sulfated proteoglycans (61). Their studies suggest that hydrocarbon
stapled peptides access the cytosol primarily through clathrin/claveolin-independent
endocytosis

triggered

by

association

with

negatively

charged

membrane

components, similar to traditional cationic and amphipathic CPPs. Uptake efficiency
was also found to correlate strongly with the extent of helical stabilization. When
stapled in different locations, a peptide derived from the BH3 domain of the BID
apoptotic effector protein exhibited differing levels of α-helicity by circular dichroism
(CD) spectroscopy and significantly lower endosomal uptake was associated with
peptide variants that had less-stabilized helical structure (62). Several stapled
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peptides have been shown to be successful at crossing the cell membrane to disrupt
PPIs, most notably in the case of inhibitors of the MDM2/MDM4:p53 interaction.
ALRN-6924—a stapled peptide mimetic of the MDM2/MDM4 binding region of p53—
efficiently permeates cell membranes to mediate its effect on MDM2/MDM4 and is
currently in phase 2 clinical trials for the treatment of T-cell lymphoma (Figure
2C)(63,64). Several other intracellular PPIs have been successfully targeted using
stapled peptides, including the NOTCH transcription factor complex (65), Wnt
signaling through β-catenin (66), and the PRC2 complex (67). However, it should be
noted that only a small subset of stapled peptides are cell permeable and that
endosomal escape remains a challenge for this class of molecules.
Cyclic peptide screening and cell permeability
mRNA display is an in vitro directed evolution method developed by Roberts
and Stzosak to screen libraries of randomized peptides for desired properties (e.g.
binding to a target) by forming a covalent link between each peptide and its
encoding mRNA (68). This allows functional molecules to be rapidly identified by
DNA sequencing following selection. As a method, mRNA display has significant
advantages over older biological display methods such as phage or yeast display
since the size of the library is not limited by the transformation efficiency of the host
organism. mRNA display libraries can reach sizes >1015 unique sequences while
phage

display

libraries

are

orders

of

magnitude

smaller

(~1011

unique

sequences)(69). Post-translational chemical modification of mRNA Display libraries
can also be carried out without concern for the molecular surface, greatly expanding
the potential chemical complexity of the library. Compared to ribosome display,
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mRNA display suffers far
fewer

confounding

effects from the surface
on which the peptide is
displayed (70). Since its
invention, mRNA display
has been used to design
numerous high affinity
peptides for targets such
as

G-protein

coupled

receptors (8), boxB RNA
(71), and PDL-1 (72)
among

many

Extensions
technology
large

others.
of

to

the
evolve

macromolecules

Figure 3: mRNA Display and SUPR mRNA Display. A) Diagram of mRNApeptide fusion. During translation of the ligated mRNA, puromycin can enter the
active site of the ribosome to form a covalent amide linkage between the
peptide and its encoding genetic information. B) SUPR peptide mRNA display
selection scheme outlining the steps performed in a round of SUPR selection,
in this case against the target LC3A

like fibronectin (73) and single-chain antibodies (74) have also been achieved.
The process of an mRNA display selection begins with the design of a
randomized dsDNA library. Libraries can be either totally naïve or a partial
randomization of an existing sequence and as many as twelve codons can be fully
randomized (>1015 unique sequences) with complete library coverage before issues
of translation scale arise. After assembly, the dsDNA library is transcribed to mRNA
in vitro and ligated to puromycin by a poly-dA linker. Puromycin acts as an
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aminoacyl-tRNA mimetic; during in vitro translation of the library it can enter the
active site of the ribosome and cause the ribosome to stall. Subsequent amide bond
formation between the primary amine of puromycin and the C-terminus of the
growing peptide yields a covalent linkage between the translated peptide and its
encoding mRNA (Figure 3A). The ligated mRNA libraries are translated in vitro
using rabbit reticulocyte lysate depleted of endogenous mRNA. Following translation
the mRNA-peptide fusions can be purified from the translation mixture using a polydT resin that associates with the poly-dA linker between the peptide and its
conjugated mRNA (75). Purified mRNA-peptide fusions are typically reverse
transcribed to form an mRNA-DNA duplex to stabilize the genetic information and
prevent inadvertent selection of aptamers. The resulting peptide-DNA-RNA
conjugates are then screened against an immobilized target protein for binding.
Following extensive washing to remove non-functional sequences, PCR is
performed to amplify the genetic information of peptide sequences which bind
strongly to the target. This yields an enriched library of dsDNA that serves as the
basis for the next round’s library. From here the process of selection can be
repeated as many times as necessary for the library to converge (typically 5-7
rounds) at which point the final pool can be sequenced to identify candidates for
further investigation.
While an eminently powerful tool for identifying peptide sequences that bind
to target proteins with antibody-like affinities and specificity, the products of mRNA
display selections suffer from all the traditional liabilities associated with linear
peptides. Linear peptides are often disordered which impairs binding affinity and
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imparts susceptibility to enzymatic hydrolysis in the face of serum and intracellular
proteases. Linear peptides are almost always non-cell permeable further reducing
their potential for translation. Scanning Unnatural Protease Resistant (SUPR)
peptide mRNA display represents an advancement on the original mRNA display
technology which aims to solve the issues of conformational entropy and protease
susceptibility (Figure 2B). During SUPR peptide mRNA display selections, amber
codon nonsense suppression is utilized during in vitro translation to facilitate
incorporation of a single non-proteogenic amino acid into translated peptides. While
any non-proteogenic amino acid may be chosen, N-methylated amino acids such as
N-methyl-L-alanine or N-methyl-L-norvaline are commonly selected to increase
resistance to proteases (11). In addition to unnatural amino acid incorporation,
SUPR peptide mRNA display employs macrocyclization to reduce conformational
entropy and improve stability. A common method to cyclize peptides involves
designing the SUPR peptide libraries with a locked C-terminal lysine immediately
adjacent to the randomized region. Macrocyclization can then be readily achieved
between the sidechain of lysine and the N-terminus of the peptide using an aminereactive

crosslinker

such

as

disuccinimidyl

glutarate

(DSG)

using

N-

hydroxysuccinimide ester chemistry (8,76). As a final modification of the mRNA
display selection procedure, SUPR peptide mRNA display selections will typically
incorporate an additional selection pressure for protease resistance by incubating
the cyclized mRNA-peptide fusion library with strong protease—such as proteinaseK—immediately prior to each round of binding selection (Figure 3B). These
strategies tend to produce hits that not only have high affinity and selectivity for the
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target protein of interest, but also superb protease stability. Selected peptides are
frequently observed to incorporate multiple N-methyl amino acids resulting in
biological half-lives on the order of weeks in human serum (ex vivo)(11).
While designed to produce serum-stable peptides that bind targets with
antibody-like affinities, the strategies employed by SUPR peptide mRNA display
produce peptides that possess many of the features thought to convey cell
permeability. As we have discussed already, the combination of N-methylation of the
peptide backbone and cyclization of peptides with a hydrophobic cross-linker has
been shown to dramatically improve the intrinsic cell permeability of peptides.
Macrocyclization-promoted formation of intramolecular hydrogen bonding and Nmethylation of the peptide backbone reduce the number of solvent accessible HBDs
in the peptide backbone which reduces the desolvation penalty the peptide pays to
associate with the outer surface of the cell membrane, an essential first step to both
passive diffusion and endocytosis. Hydrocarbon stapling utilizes a hydrophobic
crosslinker between the sidechains of the i,i+4 residues of peptides to enforce αhelicity and it has been shown that endosomal uptake and escape efficiencies of
stapled peptides are dependent on the extent of helix stabilization induced by the
staple (62). The DSG crosslinker utilized in SUPR mRNA display selections is
chemically similar to the hydrocarbon bridges in stapled peptides and may convey
similar properties of improved endosomal uptake by structural stabilization.
SUPR peptides may be ideal scaffolds for inhibiting intracellular diseasegenerating PPIs. The directed evolution technology is highly efficient in generating
macrocyclic peptides that bind targets with antibody-like affinity, specificity and
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sufficient surface area to disrupt PPIs while remaining highly resistant to serum
proteases. SUPR peptide sizes (~1200-2000 Da) are not too large to be
endocytosed and the combination of macrocyclization and backbone N-methylation
conveys many of the properties characteristic of peptides that undergo highly
efficient endosomal uptake and escape into the cytosol.
SUPR peptide selections for autophagy PPIs
Macroautophagy, or simply autophagy, is a catabolic, bulk-degradation
cellular housekeeping process that may provide an ideal target for the development
of cell-permeable SUPR peptide PPI inhibitors. Autophagy is mediated by highly
conserved molecular machinery that typically operates at a low basal level and is
dramatically upregulated in response to cellular stress such as nutrient deprivation
(77,78). Upon initiation of autophagy signaling, isolation membranes in the cytosol
originating from the endoplasmic reticulum are expanded, eventually forming doublemembrane vesicles called autophagosomes. These autophagosomes encapsulate
portions of the cytosol containing proteins and organelles during their expansion,
and prior to closure, a number of autophagy adaptor proteins transport damaged or
superfluous proteins and organelles to the autophagosome interior. The mature,
closed, autophagosome eventually fuses with the lysosome—forming a vesicle
called the autolysosome—and hydrolytic lysosomal proteases degrade the contents
of the vesicle to monomers which are used for downstream metabolism. In this
manner autophagy lives up to the literal translation of its name: self-eating. Internal
components of the cell are broken down into basic metabolites to fuel essential
processes (Figure 4A).
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As an adaptive stress response, autophagy allows cells to survive transient
periods of stress. Basal autophagic flux is slow, but can be rapidly upregulated to
break down nonessential cellular machinery during periods when the cell cannot
acquire sufficient nutrients from its environment. Like many processes necessary for
cellular health, autophagy can be co-opted by disease. Many types of cancer—
including ovarian (79,80), breast (81,82), esophageal (83), colon (84), and
pancreatic (85–87)—constitutively activate autophagy far above basal levels in order
to survive the nutrient deprived conditions imposed on the developing tumor
microenvironment by poor and dysregulated vasculature. Additionally, autophagy is
known to be upregulated in response to internalization of cytotoxic agents or
extreme internal stress such as can be caused by radiation-induced DNA damage
and free radical generation. Many cancers will activate autophagy in response to
chemotherapeutics (83,88–90) and radiation (91–93)—particularly, recurrent,
metastatic disease that has been treated previously. Because of this, there is
significant clinical interest in inhibitors of autophagy as an adjuvant to increase or
restore the effectiveness frontline chemotherapeutics and radiation. Chloroquine and
hydroxychloroquine have been investigated exhaustively in combination with standof-care cancer therapies. Unfortunately, these compounds don’t specifically target
autophagy. Rather, they are non-specific lysosomtropic agents which impair the
function of lysosomes by raising lysosomal pH and inhibiting the activity of lysosomal
enzymes.

As

a

consequence,

chloroquine

and

hydroxychloroquine

incur

unacceptably high levels of normal tissue toxicity at therapeutically relevant doses.
While the toxicity of CQ and HCQ have recently come to the attention of the public
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as a result of the
SARS-CoV-2
epidemic

(94),

the

toxic effects of CQ
and HCQ have long
been

understood.

Therapeutically
relevant doses can
lead to rapid onset of
retinopathy

Figure 4: The autophagy machinery and the role of LC3. A) Diagram of the
autophagy machinery. Following initiation of autophagy, LC3 is lipidated and
embedded in the autophagosome surface where it facilitates cargo recruitment and
closure of the autophagosome. B) LC3 PPIs are mediated by a consensus amino acid
motif in its binding partners that recognizes two hydrophobic binding pockets on the
surface of LC3 shown here in red (W-site) and green (L-site). This hot spot is
recognized by LC3-interacting motifs (LIMs) which contain the consensus sequence
W/Y/F-XX-L/V/I.
We hypothesized that SUPR mRNA display could generate cell
permeable macrocyclic peptides that recapitulate this motif and effectively inhibit LC3
PPIs.

(95,96),

hypotension,

and

potentially

fatal

ventricular
tachycardia

(97).

What is needed are
inhibitors

of

the

autophagy machinery itself. These compounds would block only the PPIs relevant to
the normal functioning of the autophagic machinery without inducing significant
toxicity in healthy cells.
We hypothesized that SUPR peptides might be the ideal class of compounds
to inhibit the autophagy machinery in a targeted manner. While the signaling,
initiation, and maturation of autophagosomes is a complex process that involves
hundreds of PPIs, one particular family of proteins stands out as a crucial element.
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Microtubule-associated protein light-chain 3 (LC3) is a small 14 kDa protein built
around a ubiquitin core that plays an essential role in the maturation of
autophagosomes and transport of cargo into their interior. Following translation, LC3
is acted upon by the autophagy-related protein Atg4 which cleaves the C-terminus of
LC3 to expose a glycine residue (LC3-I). When autophagy is initiated, LC3-I is
modified by a series of protein complexes in an E1- and E2-like manner to conjugate
the membrane lipid phosphatidylethanolamine (PE) to its newly exposed C-terminal
glycine residue (LC3-II). LC3-II is then embedded in the interior and exterior
surfaces of the nascent autophagosome membrane where it plays an essential role
in the expansion and closure of the autophagosome. Additionally, both during and
following the closure of the autophagosome, LC3 is heavily involved in the
recruitment of cargo to the autophagosome interior. Many autophagy related cargo
adapter proteins—such as p62 (SQSTM1), NIX, NBR1, and NDP52—transport
organelles, proteins, and protein aggregates to the vicinity of the autophagosome
and then interact with LC3 to transport their cargo to the autophagosome interior
(98). The vast majority of LC3’s PPIs—including those associated with cargo
adapter proteins and the protein machinery that post-translationally modifies and
lipidates LC3—occur via a “hot spot” on the surface of LC3 made up of two
hydrophobic binding pockets. These two binding pockets recognize a common
amino acid motif of (W/F/Y)-XX-(L/I/V) where X can represent any amino acid (99–
101). This motif—termed the LC3 interacting motif (LIM)—is found in nearly all of
LC3’s PPI partners (Figure 4B).
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The combination of LC3’s essential role in autophagosome maturation and
the universal nature of the LIM in mediating its function makes the hot spot of LC3
an appealing target for specific inhibition of autophagy. Small molecules are unlikely
to be effective at disrupting LC3 hot spot PPIs since it is made up of two pockets
spaced over a moderate surface area rather a single pocket. Likewise, biologics
would not be effective inhibitors of LC3 PPIs since the LC3 machinery operates
exclusively in the cytosol. We hypothesized that SUPR peptide mRNA display might
represent an ideal technology to develop compounds that possess sufficient size to
mimic the LIM and disrupt LC3 PPIs while retaining cell permeability and efficient
cytosolic access.
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CHAPTER TWO
DIRECTED EVOLUTION OF CYCLIC PEPTIDES FOR
INHIBITION OF AUTOPHAGY
Introduction
Macroautophagy (hereafter autophagy) is a conserved cellular catabolic
process responsible for recycling damaged, misfolded, or superfluous cytosolic
proteins and organelles (77,78,102,103). Upon initiation of autophagy, intracellular
double membrane vesicles called autophagosomes are formed which engulf and
sequester organelles, lipids, starches, and proteins (104). Cargo adapter proteins
(e.g. p62) facilitate the transfer of organelles and protein aggregates to the interior of
the autophagosome (100,105,106).

Mature autophagosomes then fuse with

lysosomes to degrade their contents to monomers for downstream anabolism and
catabolism. Basal autophagy maintains cellular homeostasis through clearance of
superfluous or damaged proteins and organelles, and autophagic flux is upregulated
as an adaptive response to nutrient deprivation and exposure to cytotoxic agents. In
recent years it has become increasingly apparent that autophagy upregulation plays
a major role in the development and response to treatment of cancer (107–112).
Many tumors types—including ovarian (79,80,113), pancreatic (85–87,114–116),
breast (81,82,117), and colon cancers (84)—depend on persistent activation of
autophagy to sustain growth in the poorly vascularized, hypoxic, and nutrientdeprived conditions of the tumor microenvironment (118,119). Activation of
autophagy in response to chemotherapy (83,88–90,113,120,121) and radiation (91–
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93,122–124) has been identified as a major contributing factor to acquisition of
treatment resistance (108,112,125).
As a result of its central role in tumor development and treatment resistance,
there has been intense clinical interest in autophagy inhibitors to augment frontline
radiation and chemotherapy treatment strategies. As of 2019, over 50 Phase-I and
Phase-II clinical trials focusing on autophagy inhibitors to treat cancer have been
with the vast majority combining chloroquine (CQ) or hydroxychloroquine (HCQ) with
current standard-of-care therapies (126,127). Unfortunately these non-specific
lysosomotropic compounds inhibit the function of lysosomes in normal tissue leading
to unwanted toxicities at therapeutically relevant doses (128).

The narrow

therapeutic window of chloroquine-based drugs argues for the development of
targeted agents that selectively disrupt the fundamental protein-protein interactions
(PPIs) of the autophagic machinery.
Microtubule-associate protein light chain 3 (LC3) is a 14 kDa ubiquitin-like
protein that is essential to the maturation of the autophagosome, delivery of cargo to
the autophagosome interior, and fusion with the lysosome. Following translation,
pro-LC3 is cleaved by Atg4 to expose a C-terminal glycine residue (LC3-I) which is
uniformly distributed throughout the cytosol. Upon induction of autophagy, LC3-I is
modified by a series of autophagy-related proteins leading to conjugation of
phosphatidylethanolamine (PE) to the exposed C-terminus (LC3-II). LC3-II is
embedded in both inner and outer membranes of the nascent autophagosome
where it facilitates its elongation and closure. Membrane-bound LC3-II also interacts
with autophagy adapter proteins such as p62 (SQSTM1), NIX, NBR1, and NDP52 to
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transport damaged organelles and protein aggregates to the autophagosome
interior. Disruption of LC3 processing and embedding—i.e. through LC3 knockout or
knockout/knockdown of Atg5 or Atg7 which mediate LC3 conjugation to PE—leads
to dysfunctional phagophore elongation, hampered autophagosome closure, and
inhibition of fusion between the autophagosome and lysosome (107,129).
Due to its essential role in the maturation of the autophagosome, blockade of
LC3 PPIs represents a promising strategy for targeted autophagy inhibition. The
vast majority of LC3 PPIs are thought to occur via a “hot spot” on the surface of LC3
consisting of two hydrophobic binding pockets which recognize a core amino acid
motif—(W/F/Y)-XX-(L/I/V) where XX can be any amino acids (99,100,130). This
sequence is referred to as the LC3-interacting motif (LIM) and is found in nearly all
proteins that interact with LC3.
Inhibiting PPIs with small molecules remains challenging due to their small
size and molecular radius (131,132).

Small, linear peptides, which have shown

great promise as PPI disruptors in vitro, cannot readily cross biological membranes
and suffer from poor serum stability. LC3-binding peptides derived from naturally
occurring LIMs possess relatively low affinities (mid to low micromolar range) and
would likely suffer from the same stability and permeability issues that typically limit
the usefulness of small, linear peptides in vivo (133).
In natural product space, there are numerous examples of cyclic peptides that
readily cross the cell membrane (e.g. Microsytin LR, α-amnitin, and phalloidin (134–
136)), exhibit nanomolar potencies against intracellular targets, and show sufficient
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biostability for in vivo applications (137,138). Consequently, macrocyclic peptide
scaffolds have received a great deal of attention as a means to generate PPIdisrupting compounds with drug-like affinity, stability, and cell permeability (15).
One strategy for designing cell-permeable cyclic peptides focuses heavily on Nmethylation of amino acids within the context of macrocyclic scaffolds. The work of
Lokey and co-workers, for example, has shown that extensive methylation of
backbone amides within the peptide macrocycle effectively eliminates hydrogen
bonds between backbone amide protons and water and results in significant
enhancement of passive cell permeability (139,140).

Pei and co-workers have

elegantly demonstrated that cyclic, amphipathic cell-penetrating peptides can drive
the uptake of otherwise non-permeable peptide and protein cargo. These cyclic
sequences can be incorporated within the context of bioactive macrocycles to
greatly enhance cell uptake with minimal perturbation of biological function (141).
The use of “stapled” peptides represents a third approach to enhancing cell uptake
(61). In this approach, ring-closing metastasis is employed to cross-link the side
chains of α-helical peptides, providing conformational constraint and stabilizing i+4
and i, i+7 hydrogen bonding patterns (61). This approach has been used to design
proteolytically stable, cell permeable peptides that target MDM2/4 and inhibit
proteasome-mediated degradation of p53 (142).
Scanning Unnatural Protease Resistant (SUPR) mRNA display provides a
method to rapidly evolve macrocyclic, protease-resistant peptides for in vivo
applications (143,144). SUPR peptide mRNA Display is a recent advancement of
mRNA display (6,69) that integrates disuccinimidyl glutarate-based macrocyclization,
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incorporation of non-proteogenic N-methyl amino acids, and pre-screening for
protease resistance (76,145). This technique leads to the selection of macrocyclic
peptides with high target affinity and dramatically enhanced stability to hydrolytic
degradation. The SUPR peptide scaffold also recapitulates many of the
physiochemcial properties of cell permeable macrocyclic peptides (backbone amide
N-methylation and a hydrophobic crosslinker) suggesting that SUPR peptide may
possess the requisite cell permeability for disruption of intracellular PPIs.
We carried out SUPR mRNA display selections against recombinant LC3 to
identify LC3-binding SUPR peptides with sufficient affinity, stability, and cell
permeability for in vivo applications. The most promising candidate from the
selection (SUPR4B1W) binds to LC3A and LC3B with mid-nanomolar affinity and
was significantly more stable to proteolytic degradation than its linear and nonmethylated counterparts. SUPR4B1W sensitized multiple cancer cell lines to
cisplatin treatment, resulted in accumulation of intracellular p62, and significantly
modulated the LC3-I/LC3-II ratio in cell culture. Finally, SUPR4B1W, in combination
with carboplatin, effectively prevented intraperitoneal tumor outgrowth in orthotopic
mouse models of ovarian cancer after four weeks of treatment.
Materials & Methods
Cell Lines
OVCAR5, OVCAR8, and HEY cell lines were maintained in RPMI 1640
medium supplemented with 10% fetal bovine serum, 2 mM L-Glutamine, 1 mM NaPyruvate, and 1% (v/v) penicillin-streptomycin. SKOV3 cells were maintained in in
McCoy’s 5A medium supplemented with 10% fetal bovine serum, 2 mM L39

Glutamine, and 1% (v/v) penicillin-streptomycin. MDA-MB-231, PANC-1, and MIA
PaCa-2 cell lines were maintained in DMEM medium supplemented with 10% fetal
bovine serum and 1% (v/v) penicillin-streptomycin.
HeLa cells were maintained in RPMI 1640 supplemented with 5% fetal bovine
serum. HeLa cells stably expressing EGFP-LC3B were generated using pEGFP-LC3
(Addgene #24920). HeLa cells were directly transfected with pEGFP-LC3 using
Mirus TransIT-LT1 transfection reagent and then maintained in RPMI 1640
supplemented with 5% fetal bovine serum and 400 µg/mL active G418 for 14 days.
Single-cell sorting was performed on a FACSAria IIIu instrument. HeLA-GFP-LC3B
cell lines derived from single cells were maintained in RPMI 1640 supplemented with
5% fetal bovine serum and 200 µg/mL active G418.
Expression and Purification of Recombinant LC3
pQTEV-MAP1LC3A vectors for expression and purification of N-terminally
polyhistidine tagged recombinant LC3A were ordered through Addgene (Plasmid
#34824) and transformed into BL21-DE3 pLysS E. coli (Promega). 2 Liters of LB
media were inoculated from overnight cultures and grown to an OD600 of 0.6 before
expression was induced with IPTG at a concentration of 0.6 mM for 3 hours. Cell
pellets were resuspended in 15 mL equilibration buffer (20 mM HEPES pH 7.2, 200
mM NaCl, 10 mM imidazole) and lysed by sonication. Clarified lysate was incubated
with 1 mL Ni-NTA resin for one hour, loaded onto a fritted column, and flow-through
eluted. Resin was washed four times with equilibration buffer and the protein was
eluted with 15 mL elution buffer (20 mM HEPES pH 7.2, 200 mM NaCl, 250 mM
imidazole). Eluted protein was buffer exchanged against dialysis buffer (20 mM
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HEPES pH 7.2, 200 mM NaCl, 25% glycerol) using 3,000 MWCO dialysis tubing
(Fisher) and concentrated by Amicon Ultracel 3k centrifugal filters (Millipore) to a
final concentration of 1.4 mg/mL (7 mg/L total yield). His6-LC3A was biotinylated
using 5x molar excess biotin-NHS (Sigma). The reaction was incubated on ice for 2
hours before excess biotin-NHS was removed by 7,000 MWCO Zeba spin column
(Thermo). Biotinylation was confirmed by HABA-Avidin assay (Pierce) and final
concentration of biotinylated His6-LC3A was measured at 1.25 mg/mL by BCA
assay.
pDEST15-LC3A and pDEST15-LC3B constructs for N-terminally tagged GSTLC3A and GST-LC3B were provided by Dr. Terje Johansen1,2. Transformation and
expression of plasmids were performed as described above. Clarified lysate was
incubated with 1 mL glutathione agarose (Goldbio) for one hour, loaded onto a fritted
column, and flow-through eluted. Resin was washed four times with equilibration
buffer and the protein was eluted with 15 mL elution buffer (20 mM HEPES pH 8.0,
200 mM NaCl, 10 mM reduced glutathione). Eluted protein was exchanged against
dialysis buffer (20 mM HEPES pH 7.2, 200 mM NaCl, 25% glycerol) using 3,000
MWCO dialysis tubing (Fisher) and concentrated by Amicon Ultracel 3k centrifugal
filters (Millipore) to a final concentration of 1.18 mg/mL GST-LC3A and 1.13 mg/mL
GST-LC3B by BCA assay.
Synthesis of N-methyl Alanine amber codon suppressor
NVOC-N-methyl-L-alanine cyanomethyl ester was synthesized according to
previously described protocols for conjugation to the dinucleotide pdCpA and ligation
to the amber suppressor THG73 tRNA. NVOC-Cl (269 mg, 970 µmol, Sigma) was
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dissolved in 8 mL THF and added dropwise to N-methyl-L-alanine (100 mg, 969.7
µmol, Sigma) dissolved in 2 mL sodium carbonate. 10 N NaOH was added to bring
the reaction mixture to pH > 10 and the reaction mixture was stirred at room
temperature protected from light for 3 hours. Solvents were removed in vacuo and
the dried compound was dissolved in 3 mL dry DMF to which 2 mL chloroacetonitrile
and 600 µL triethylamine were added. The reaction was stirred under nitrogen
overnight before the solvents were removed in vacuo and the remaining solid was
purified by silica gel flash chromatography.
NVOC-N-methyl-L-alanine cyanomethyl ester (12.7 mg, 33.2 µmol) and
pdCpA (5 mg, 8.3 µmol, TriLink Biotechnologies) were dissolved in 400 µL dry DMF
under nitrogen and stirred at room temperature protected from light for 4 hours
before quenching the reaction with 20 µL ammonium acetate (25 mM, pH 4.5). The
crude product was purified by reverse phase preparative HPLC using a gradient of
ammonium acetate (25 mM, pH 4.5) to acetonitrile and the fractions corresponding
to the product were combined and lyophilized yielding 3 mg of NVOC-N-Methyl-LAlanine-pdCpA (36.1% yield). Product was confirmed by observing the [M+H]+ peak
at MW = 961.54

(expected 960.21) using electrospray ionization mass

spectrometry.
pUC19-THG73tRNA plasmid (a gift from Dennis Dougherty, California
Institute of Technology) containing the gene for THG73 amber codon suppressor
tRNA was PCR amplified and linearized by overnight FokI digestion at 37C. THG73
tRNA was transcribed in vitro by T7 RNA polymerase, purified by Urea-PAGE and
dissolved in water (2 µg/µL final concentration).
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NVOC-N-methyl-L-alanine-pdCpA was ligated to THG73 tRNA just prior to its
use in in vitro translation reactions. THG73 tRNA (20 µg in 10 µL water) and HEPES
(20 µL, 10 mM, pH 7.5) were combined and heated at 95 °C for 3 minutes, then
cooled to 37 °C. NVOC-N-Methyl-L-Alanine-pdCpA (8 µL, 3 mM in DMSO) was
added to the tRNA-HEPES mixture along with water (30 µL), T4 RNA Ligase (4 µL,
New England Biolabs), and 10x T4 Reaction Buffer (8 µL, New England Biolabs).
The reaction was incubated at 37 °C for 65 minutes, extracted with 25:24:1
phenol:chloroform:isoamyl alcohol (Sigma), and precipitated with >3 volumes cold
ethanol at -80 °C. The precipitate was dried by vacuum, dissolved in 20 µL 1 mM
sodium acetate, quantified by measuring A260, and adjusted to a final concentration
of 1 µg/µL.

Immediately prior to in vitro translation the AA-tRNA solution was

deprotected by short-wave UV for 15 minutes.
SUPR mRNA Display Library Preparation
To perform selections, we assembled a DNA library encoding eight random
positions between an N-terminal methionine residue and a C-terminal lysine residue.
The library was constructed by the PCR amplification of the antisense template oligo
(5’ TCC GCT GCC GGA TTT SNN SNN SNN SNN SNN SNN SNN SNN CAT TGT
AAT TGT AAA TAT AAT T 3’ where N= A, C, G or T and S = C or G) with the
primers MKForward (5’ TAA TAC GAC TCA CTA TAG GGA CAA TTA CTA TTT
ACA ATT ACA 3’) and MKReverse (5’ GCC AGA TCC GCT GCC GGA TTT 3’). In
addition to the open reading frame, the DNA library contains a T7 promoter
sequence and a ribosome binding site.
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The mRNA display library was generated by in vitro transcription of the DNA
library. Transcription was performed by incubating DNA libraries with transcription
buffer (80 mM HEPES-KOH, pH 7.5, 2 mM spermidine, 40 mM DTT, and 25 mM
MgCl2) and rNTP mixture (4 mM ATP, GTP, CTP, UTP) at 65 °C for 15 minutes
before cooling briefly at room temp and adding T7 RNA polymerase. Transcription
reactions were allowed to proceed overnight at 37 °C and were terminated by phenol
chloroform extraction and ethanol precipitation. The mRNA library was then purified
by running denaturing Urea-PAGE, cutting out mRNA bands, and recovering by
electroelution.
The mRNA library was then ligated at the 3’ end to a puromycin-DNA linker
(pF30P - 5' 8AA AAA AAA AAA AAA AAA AAA A77 7AC C6 3') where 6 =
puromycin CPG, 7 = spacer phosphoramidite 9, 8 = phosphate). Puromycin acts as
an aminoacyl tRNA mimetic that can enter the active site of the ribosome to form a
covalent link between the translated peptide and its encoding mRNA resulting in an
mRNA-peptide fusion. Ligation reactions were performed by incubating 3000 pmol of
mRNA library with 1.2 molar excess PF30P, 1.4 molar excess splint oligo (5’ TTT
TTT TTT TTT TGC CAG ATC CGC TG 3’), and T4 DNA ligase at room temperature
for 75 minutes. The ligated mRNA library was then purified by Urea-PAGE and
electroelution as described above.
mRNA Display Selection
In vitro translations were performed using rabbit reticulocyte lysate kits
(Ambion). To assemble the translation reaction 10 pmol ligated mRNA library was
added to rabbit reticulocyte lysate (17 µL), EasyTag [35S]-Methionine (3 µL, 8
44

µCi/µL, PerkinElmer), amber suppressor tRNA charged with N-Methyl Alanine (2.25
µL, 1 µg/µL), 20x high salt mix (1.25 µL, KOAc 3 M, MgOAc 10 mM, creatine
phosphate 200 mM, and 1 mM of each amino acid except methionine). After a 70
minute incubation at 30 °C the translation mix was supplemented with 100 mM KCl
and 0.5 mM MgCl2 to promote the formation of mRNA-peptide fusions. mRNApeptide fusions were purified from the translation mix using oligo-dTcellulose (GE)
which selectively binds to the poly dA linker between the mRNA template and
puromycin. Oligo dT cellulose was washed with dT binding buffer (Tris-HCL pH 8.0
20 mM, NaCl 1 M, EDTA 1 mM, Triton-X 0.2% (v/v)) and translation mixes were
rotated with 10 mg of oligo dT cellulose in 500 µL dT binding buffer at 4 °C for 60
minutes. The oligo-dT cellulose was then washed with dT wash buffer (Tris-HCL pH
8.0 20 mM, 300 mM NaCl) and mRNA–peptide fusions were eluted in 60 °C water.
Following dT purification, mRNA-peptide fusions were ethanol precipitated
and resuspended in 50 mM phosphate buffer pH 8.0 for cyclization between the
primary amine of the lysine side chain and at the N-terminal amine using the
crosslinker disuccinimidyl glutarate (DSG). The cyclization reaction was carried out
by adding DSG to the mRNA-peptide fusions to a final concentration of 200 µg/mL
and rotating at room temperature for 60 minutes. Cyclized mRNA-peptide fusions
were then dT purified using the method described above. Following purification,
mRNA-peptide fusions were reverse transcribed by M-MulV reverse transcriptase
(NEB). Reverse transcribed fusions were subjected to protease screening by
incubating with proteinase-K agarose (Sigma) for 30 s before filtering with Spin-X
microcentrifuge column. To eliminate sequences with significant off-target binding to
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the resin, proteinase-treated fusions were incubated with streptavidin-agarose (Life
Technologies) at 4 °C for 60 minutes before recovering unbound fusions using SpinX microcentrifuge column.
Selection targets were prepared by incubating streptavidin-agarose with 1.5x
molar excess biotinylated-LC3A at 4 °C with rotation for 30 minutes to saturate the
resin with target. The immobilized target was then washed thoroughly with selection
buffer (20 mM HEPES-KOH pH 7.5, 150 mM NaCl, 0.2% (v/v) Tween-20, 1 mg/mL
BSA, 50 µg/mL tRNA, 1 mM β-mercaptoethanol). Selections were carried out by
incubating fusions with immobilized target with rotation for 2 hours. Selection
incubations were carried out at 4 °C for the first four rounds of selection and then
split into parallel selections carried out at 25 °C or 4 °C thereafter. Following
incubation, the selection resin was washed 3 times with selection buffer and filtered
with a Spin-X column. The resin was then washed two additional times in selection
buffer without BSA or tRNA and bound fusions were eluted in 0.15% sodium dodecyl
sulfate (SDS) (Thermo-Fisher). SDS was subsequently precipitated using SDS-Out
(Thermo-Fisher) and eluted fusions were filtered and ethanol precipitated. The
precipitated pellet was resuspended in dH2O and one fifth of the total volume was
subjected to PCR amplification using the MKFor and MKRev primers. Small volumes
of PCR product were removed every 3 PCR cycles and tested by 4% agarose gel to
identify formation of the amplified product. The remaining eluted fusions were
amplified using the minimum PCR cycles as defined in the previous step. Further
selection rounds were conducted using previous round’s enriched dsDNA library.
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The library was considered converged when the number of PCR cycles required to
recover the enriched dsDNA library did not decrease in three consecutive rounds.
Sanger Sequencing
After libraries converged, the final pool was TOPO-TA cloned into pCR™IITOPO® vector (Thermo-Fisher), transformed into One Shot TOP10 chemically
competent E. coli (Thermo-Fisher), and plated on ampicillin-agarose to isolate
individual sequences from the final selection pool. Twelve colonies from each
parallel selection were selected at random and plasmid minipreps (Life
Technologies) were prepared from 5 mL overnight cultures. Amplified plasmids were
submitted for Sanger sequencing and analyzed using FinchTV software. Peptide
Synthesis and Cyclization
Peptide Synthesis and Cyclization
Peptides were synthesized using a Prelude automated peptide synthesis
instrument (Protein Technology, Inc.). 2-chlorotrityl resin (0.439 g, 0.5 mmol,
Advanced Chemtech) was swollen in DMF for 1 hour and washed twice with 5 mL
DMF. The initial C-terminal amino acid coupling to the resin was performed manually
prior to automated synthesis of peptides. 2 equivalents Fmoc-propargylglycine (1
mmol, 335 mg) and 3 equivalents N,N-diisopropylethylamine (DIEA, 1.5 mmol, 262
µL, Sigma) were added to the swelled resin in 6 mL DMF and rotated at room
temperature

for 1 hour.

To synthesize each peptide, 100 mg of Fmoc-

propargylglycine resin was loaded onto the automated synthesis instrument and
synthesis was performed with 3 equivalents of Fmoc amino acid (Oakwood
Products, Inc.), DIEA, and N,N,N′,N′-Tetramethyl-O-(1H-benzotriazol-1-yl)uronium
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hexafluorophosphate (HBTU, Oakwood Products, Inc.) in N-methyl Pyrrolidone
(NMP). A total of 3 coupling reactions (10 minute duration) were performed for each
amino acid building block. Deprotection of Fmoc groups was achieved using 20%
(v/v) piperidine in NMP. After synthesis and final deprotection, resin was washed 5x
with NMP (1.5 mL, 2.5 minutes), 5x with DCM (1.5 mL, 2.5 minutes), and dried
under vacuum for 1 hour. Peptides were cleaved from the resin with 95% (v/v)
trifluoroacetic acid, 2.5% (v/v) water, 2.5% (v/v) triisopropylsilane at room
temperature for 3 hours, precipitated with cold diethyl ether, and dried under
vacuum. Crude products were purified by reverse phase preparative HPLC (Luna
Phenomenex, 5 µm C18(2), 250 mm x 21.2 mm LC column) using gradient elution
(5-95% Buffer B over 45 minutes; Buffer A dH2O + 0.1% (v/v) TFA, Buffer B CH3CN
+ 0.1% (v/v) TFA). Appropriate fractions were combined and lyophilized yielding a
white solid. Purified products were confirmed by electrospray ionization mass
spectrometry.
Amine reactive cross-linker chemistry was utilized to cyclize peptides
between the N-terminus of the peptide and the side-chain of a C-terminal lysine
residue. Purified linear peptide was dissolved in DMF and mixed with 1.1 equivalents
of disuccinimidyl glutarate (DSG) and 7 equivalents DIEA at room temperature for 3
hours. After 3 hours the reaction was quenched with hydroxylamine (10 mM final
concentration) for 15 minutes and solvent was removed in vacuo. The crude product
was dissolved in 1 mL 95:5 (v/v) dH2O:CH3CN + 0.1% (v/v) TFA and purified by
reverse phase preparative HPLC using gradient elution (5-20% Buffer B over 5
minutes, 20-95% Buffer B over 60 minutes; Buffer A dH2O + 0.1% (v/v) TFA, Buffer
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B CH3CN + 0.1% (v/v) TFA). Appropriate fractions were combined and lyophilized
yielding a white solid. Purified products were confirmed by electrospray ionization
mass spectrometry.
Fluorophore Conjugation of SUPR Peptides
Copper-catalyzed click chemistry was used to conjugate fluorescein-azide to
the side-chain alkyne of the C-terminal propargylglycine residue in SUPR peptides.
Between 2-3 µmol of each peptide was dissolved in DMSO and added to 1.2
equivalents FAM-azide, 6-isomer (50 mg/mL, Lumiprobe), 50 µL click solution (16
mg/mL CuSO4·2H2O and 30 mg/mL L-ascorbic acid in dH2O), 5 µL of tris(benzyltriazolylmethyl)amine (TBTA, 100 mg/mL in DMF). Reaction mixture was
brought to a final volume of 150 µL with dH2O and rotated at room temperature for 2
hours and purified by reverse phase preparative HPLC (Luna Phenomenex, 5 µm
C18(2), 250 mm x 21.2 mm LC column) using gradient elution (5-95% Buffer B over
45 minutes; Buffer A dH2O + 0.1% (v/v) TFA, Buffer B CH3CN + 0.1% (v/v) TFA).
Appropriate fractions were combined and lyophilized yielding a yellow-green solid.
Purified products were confirmed by electrospray ionization mass spectrometry.
Copper-catalyzed click chemistry was used to conjugate carboxy-Xrhodamine (ROX) azide to the side-chain alkyne of the C-terminal propargylglycine
residue of SUPR4B1W. 3 µmol of SUPR4B1W was dissolved in DMSO and added
to 1.2 eq ROX-azide (50 mg/mL, Lumiprobe), 50 µL click solution (16 mg/mL
CuSO4·2H2O and 30 mg/mL L-ascorbic acid in dH2O), 5 µL of TBTA (100 mg/mL).
Reaction mixture was brought to a final volume of 150 µL with dH2O and rotated at
room temperature for 2 hours and purified by reverse phase preparative HPLC
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(Luna Phenomenex, 5 µm C18(2), 250 mm x 21.2 mm LC column) using gradient
elution (5-95% Buffer B over 45 minutes; Buffer A dH2O + 0.1% (v/v) TFA, Buffer B
CH3CN + 0.1% (v/v) TFA). Appropriate fractions were combined and lyophilized
yielding a light purple solid. Purified products were confirmed by electrospray
ionization mass spectrometry
Biotin Conjugation of SUPR peptides
Copper-catalyzed click chemistry was used to conjugate biotin-azide to the
side-chain alkyne of the C-terminal propargylglycine residue in SUPR peptides. 2
µmol of SUPR4B1W was dissolved in DMSO and added to 1.2 equivalents BiotinPEG3-azide (Thermo-Fisher), 50 µL click solution (16 mg/mL CuSO4·2H2O and 30
mg/mL L-ascorbic acid in dH2O), 5 µL of tris-(benzyltriazolylmethyl)amine (TBTA,
100 mg/mL). Reaction mixture was brought to a final volume of 150 µL with dH2O
and rotated at room temperature for 2 hours and purified by reverse phase
preparative HPLC (Luna Phenomenex, 5 µm C18(2), 250 mm x 21.2 mm LC
column) using gradient elution (5-95% Buffer B over 45 minutes; Buffer A dH2O +
0.1% (v/v) TFA, Buffer B CH3CN + 0.1% (v/v) TFA). Appropriate fractions were
combined and lyophilized yielding a white solid. Purified products were confirmed by
electrospray ionization mass spectrometry.
Radiolabeled Binding Assays
Plasmid minipreps for individual clones were PCR amplified using the MKFor
and MKRev primers to obtain dsDNA for individual sequences from the final pool.
These dsDNA sequences were transcribed, ligated, and translated in the presence
of [35S]-Methionine as described above. Following incubation for 70 minutes, RNAse
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A (1 µL, 10 mg/mL, MilliporeSigma) was added to the translation mix to digest the
mRNA fused to the peptides which might impact binding. The peptides were purified
from translation using dT cellulose and subjected to cyclization as described above.
A small portion of the cyclized and purified translation product was reserved for
scintillation counting and the remaining product was incubated with biotinylatedLC3A immobilized on neutravidin-acrylamide (Thermo-Fisher) at 25 °C with rotation
for 1 hour. The incubation mix was pelleted, the supernatant reserved, and the
pelleted resin washed three times with Spin-X microcentrifuge columns. The resin
pellet and portions of the supernatant and each wash were subjected to scintillation
counting and a percentage of input activity that remained bound to the immobilized
target after washing was calculated for each clone.
Fluorescence Polarization Assays
For fluorescence polarization assays, stock solutions of GST, GST-LC3A and
GST-LC3B were adjusted to 5 µM and serially diluted to concentrations between 5
µM and 2.4 nM in triplicate in black polystyrene 96-well plates (Corning). FAMlabeled peptide was added to each well to a final concentration of 10 nM and
incubated at room temperature for 2 hours. Fluorescence polarization was measured
on a Biotek Synergy Neo Microplate Reader using a dual PMT FP 485/528 filter set.
The mean value of polarization was calculated for each sample concentration and
mean polarization values for GST were subtracted from GST-LC3 measurements to
eliminate any effects from non-specific interactions. Mean fluorescence polarization
measurements were converted to fluorescence anisotropy and fit to a one-site
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saturation binding model in Graphpad Prism 8 to calculate equilibrium binding
constants for each peptide.
Atg4B Activity Assay
LC3-AMC (R&D Systems) was diluted in Reaction Buffer (25 mM Tris, 150 mM
NaCl, 10 mM DTT) to a final concentration of 230 nM. 20 µL of LC3-AMC was
added to 5 µL SUPR peptide (1 µM, 500 µM, 250 µM, 0 µM in Reaction Buffer) in a
96-well microtiter plate pre-blocked with 5 mg/mL BSA.

After incubating for 5

minutes at room temperature, 25 µL 400 pM Atg4B (R&D Systems) was added to
initiate the reaction. The final concentrations of each component in the hydrolysis
reaction were LC3-AMC (92 nM), Atg4B (200 pM), and SUPR peptide (0-100 µM),
and the final volume was 50 µL. The hydrolysis reaction was allowed to progress at
room temperature for 40 minutes and the fluorescence measured each minute (λEX
= 380 nm, λEM = 460 nm) on a BioTek Synergy H4 microplate reader. The resulting
fluorescence at each time point (AU) was normalized to the fluorescence at t=0 to
compute the normalized product.

Each reaction condition was carried out in

triplicate and the values shown represent the mean value of three measurements.
Proteinase-K Stability Assays
Protease stability was assessed by treating peptide solutions (1 mM in PBS,
final volume 500 µl) with 0.3 mg proteinase-K agarose (Sigma). At time intervals of
0, 30, 60, 120, and 240 minutes, 50 µL samples were taken from the digestion
mixture and separated from proteinase-K agarose by centrifugal filtration with Spin-X
columns. Samples were then subjected to analytical HPLC (Agilent 1100 Series
HPLC equipped with a Phenomenex Gemini 5µ C18 110A column) using
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gradient elution (10-30% Buffer B over 30 minutes; Buffer A dH2O + 0.1% (v/v) TFA,
Buffer B CH3CN + 0.1% (v/v) TFA). Peak area was calculated for the peak
corresponding to the intact peptide for each sample and the fraction intact was
calculated for each time point. Half-lives for each peptide were calculated in
Graphpad Prism 8.
ATG8 homologue Selectivity
SUPR-4B1W-biotin was conjugated to neutravidin acrylamide by adding 2 µL,
1 mM SUPR-4B1W-biotin to 50 µL neutravidin acrylamide slurry (Thermo-Fisher)
with 200 µL binding buffer (150 mM NaCl, 50 mM Tris-HCl, pH 7.8) and rotating for 1
hr at room temperature. The immobilized peptide resin was then washed twice with
200 µL binding buffer using Spin-X centrifugal filter columns.
pET151/D-TOPO bacterial expression vectors containing the genes for LC3A,
LC3B, LC3C GABARAPL1, GABARAPL2, ATG8, and ubiquitin were designed and
ordered from Thermo-Fisher. Forward and Reverse primers were designed to allow
PCR amplification of each gene from the bacterial vectors with the addition of 5’ T7
promotor and ribosome binding site sequences. Following PCR amplification, DNA
templates were extracted with 25:24:1 Phenol:chloroform:isoamyl alcohol (Sigma)
and precipitated with >3 volumes cold ethanol at -80 °C. The centrifuged precipitate
was dried by vacuum and resuspended in 100 µL dH2O. DNA templates were
transcribed in vitro by T7 RNA polymerase and purified by UreaPAGE. 10 pmol of
each RNA template were translated in vitro in the presence of [35S]-Methionine as
described previously.
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To test selectivity of SUPR4B1W for the various ATG8 homologues, 8 µL of
translation reaction was added to 10 µL of either peptide-saturated resin (125
pmol/µL resin) or naked resin in triplicate and brought to a final volume of 50 µL with
binding buffer (20 mM HEPES-KOH pH 7.5, 150 mM NaCl). Reaction mixtures were
rotated at room temperature for 60 minutes before reaction mix was transferred to a
Spin-X column, washed 3x with 200 µL binding buffer, and washed resin was
subjected to scintillation counting.
Fluorescence microscopy
HeLa cells stably expressing eGFP-LC3 were seeded at a density of 30,000
cells/well in an 8-well chambered coverslide (Corning) 24 hours before beginning
treatment. Cells were treated with complete media supplemented with 500 nM
SUPR4B1W-ROX for 12 hours. After 12 hours cells were either starved with Hank’s
Balanced Salt Solution (Corning) or were given fresh complete media for 2 hours
and then subjected to live-cell fluorescence confocal imaging.
Quantification of colocalization between SUPR4B1W-ROX and eGFP-LC3
puncta was performed in ImageJ. Three fields of images for both starved and
unstarved treatments were selected and split into red and green channels. Cells that
were mitotic or had lost eGFP-LC3 expression were removed from the analysis.
Manders M1 and M2 coefficients were calculated using the Just Another
Colocalization (JACoP) plugin using appropriate pixel intensity thresholding to filter
background signal.
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Cellular Cisplatin Sensitization Assays
OVCAR8, OVCAR5, HEY, SKOv3, MDA-MB-231, PANC-1, and MIA PaCa-2
cells were seeded in black-walled 96-well plates at a density of 5,000 cells/well 24
hours prior to treatment. Cells were treated with SUPR peptides (50 µM) or
chloroquine (5 µM, Sigma) both in the presence and absence of cisplatin (10 µM,
Sigma) in order to determine the effect of autophagy inhibition on cellular viability in
treatment resistant cell lines. Cells were treated for a total of 48 hours (n = 6 per
treatment group) prior to viability testing by 3-(4,5-dimethylthiazol-2-yl)-2,5diphenyltetrazolium

bromide

(MTT)

assay.

Differences

in

cellular

viability

measurements between treatment groups were evaluated in R by applying two-way
ANOVA after applying a log10 or square root transformation to satisfy normality.
Cisplatin Sensitization Animal Model
Athymic nude mice were injected with 2 million OVCAR8 cells IP. Mice were
treated with SUPR4B1W (10 mg/kg) combined with carboplatin (25 mg/kg) or saline
3x per week by IP injection. Each treatment group had 8 mice, with the exception of
the group treated with carboplatin alone which had 4 mice. Treatments were
administered for 3 weeks before mice were sacrificed and tumors were dissected
and weighed. Differences in tumor mass between treatment groups were evaluated
in R by a nonparametric Mann-Whitney-Wilcoxon rank-sum test.
The assay was repeated with the additional treatment groups for
combinations of scrambled SUPR4B1W (10 mg/kg) with carboplatin (25 mg/kg) or
saline. Treatment group size was expanded to 10 mice and the duration of the
experiment was extended from 3 weeks to 4 weeks.
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Statistical Analysis
To determine the independent and interactive effects of cisplatin and
SUPR4B1W on cell viability, we used a two-way ANOVA with Type I sum of squares
on A600 absorbance. Log10 and square root transformations were used on OVCAR8
and HEY cell line absorbance data, respectively, to achieve satisfactory normality.
To determine the independent and interactive effects of carboplatin and SUPR4B1W
structure on tumor weight in mice, we used a two-way ANOVA with Type III sum of
squares. A square root transformation was necessary to handle right skewedness in
Week 4 data. Following both analyses, Tukey’s HSD via the package lsmeans was
used to determine which treatment means were significantly different from one
another.
Results & Discussion
Our goal was to generate small, protease-stable peptides with high affinity
and selectivity for LC3. In order to generate target for selection, His6-tagged LC3A
was expressed in E. coli and purified by Ni-NTA affinity chromatography (8.1 mg/L
culture). Biotinylation of recombinant LC3A was carried out using Biotin-NHS and
confirmed by HABA-Avidin assay. LC3A-biotin was then immobilized on streptavidin
agarose for selection.
Selection against LC3A using MK8 Library
Selections against LC3A were carried out using SUPR peptide mRNA
display(144). The DNA template library was designed with eight random codons and
a fixed lysine codon to allow cyclization between the side chain of lysine and the Nterminal amino group (Figure 1A).

The resulting library was translated in the
56

presence of amber
suppressor
acylated

tRNA

with

N-

methyl-L-alanine.
After seven rounds
of selection against
LC3A, binding of
the library to the
immobilized target
increased
dramatically
evidenced
reduction
number

as
by

in
of

a
the

PCR

cycles required to
amplify
enriched

the
library

Figure 1 Selection of LC3-binding SUPR peptides. A) Schematic of the MX8K
library. Eight randomized codons were installed between the N-terminal methionine
and a locked lysine residue. The library was cyclized by disuccinimidyl glutartate
(DSG)-mediated crosslinking of the N-terminal amino group and the side-chain
amino group of lysine. B) After seven rounds of selection the number of PCR cycles
required to amplify the enriched dsDNA library declined and plateaued indicating
convergence of the library. C) Sequencing of the final pool revealed three dominant
peptide families (purple, blue and red). >80% of sequences identified had
incorporated an N-methyl-L-alanine residue (Z) in the final random position of the
macrocycle. D) Each sequence was synthesized as an mRNA-peptide fusion and
panned against LC3A immobilized on streptavidin acrylamide or streptavidin
acrylamide alone (resin). Clone 4B showed 86% binding to immobilized LC3 and
minimal binding to the resin.

(Figure 1B). Sequencing revealed three dominant sequence families in the final pool
which each share a consensus motif (Y/F/N/L)-XXX-(L/V/I) analogous to canonical
LIM albeit with an additional amino acid in the spacer region (Figure 1C). It is
possible that this additional amino acid arose from the more constrained
conformation of the cyclic peptide compared to the linear LIMs found in LC3 adaptor
proteins which typically occur as elongated β-strands(101).
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Sequencing data also revealed that >80% of the clones analyzed from the
round 7 pool incorporated N-methyl-L-alanine at position 9 within the macrocycle
indicating that the selection provides a significant selection pressure for N-methyl-Lalanine incorporation at this position. In order to identify the highest affinity clones
from the round 7 pool, we performed radioligand binding assays. Individual clones
were translated as mRNA-peptide fusions in the presence of [35S]-methionine,
cyclized, and treated with RNAse A to remove the RNA portion yielding peptides
conjugated only to the poly-dA linker. Radiolabeled peptide-DNA conjugates were
then panned against LC3A immobilized on neutravidin-acrylamide or resin alone.
After an hour incubation at room temperature the resins were washed thoroughly
and analyzed by scintillation counting. While several clones showed a moderate
level of target-specific binding, clone 4B (cycl MFPHRVTAZK), hereafter SUPR4B,
showed the highest target-specific binding with 86% of the input activity remaining
bound to the immobilized target and minimal nonspecific binding to the resin alone
(Figure 1D).
Binding affinities of SUPR-4B and variants towards LC3A and LC3B
While SUPR4B appears to serve as a non-canonical LIM, we noted that
phenylalanine occurred at the first randomized position within the macrocycle.
Based on known LIM sequences, this residue is likely to interact with the W-site of
the LC3 hot spot. Although some LIMs have phenylalanine in this position, it is the
least commonly occurring amino acid residue (101). Binding to the W-site is
achieved by burying an aromatic residue into the hydrophobic pocket, and the
sidechain of tryptophan is well-suited to perform this interaction. While phenylalanine
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Figure 2: Binding affinities of SUPR4B peptides. A) Structure of SUPR4B. B) Structure of
SUPR4B1W. FAM labeled SUPR peptides were incubated with increasing concentrations of
GST-LC3A and fluorescence polarization measurements were made in triplicate. Each
measurement was converted to anisotropy and fit to a one-site saturation binding model in
Graphpad Prism to obtain the equilibrium binding constant. C) SUPR4B binds LC3A with a KD
= 360 nM D) SUPR4B1W binds LC3A with a KD = 120 nM. E) Atg4B enzyme inhibition assay.
Increasing concentrations of both SUPR4B and SUPR4B1W impair the ability of Atg4B to
cleave the C-terminus of LC3-AMC leading to diminished AMC fluorescence. Neither
scrambled peptide inhibited Atg4B’s ability to cleave LC3-AMC.

library

(1/32) or poor incorporation efficiency at the N-terminus. Our sequencing may also
have been too sparse to detect clones with tryptophan at the 2nd position and next-
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generation high throughput sequencing may reveal such clones. we hypothesized
that substitution of tryptophan for phenylalanine at position 2 in SUPR4B
(SUPR4B1W) would improve affinity for LC3.
To evaluate the impact of tryptophan substitution on binding affinity for LC3,
we measured the binding affinity of both SUPR4B (Figure 2A) and SUPR4B1W
(Figure 2B) using fluorescence polarization anisotropy. Fluorescein-labeled SUPR
peptides were incubated with increasing concentrations of GST-LC3A and GSTLC3B. Fluorescence polarization was measured (λEx = 485 nm, λEm = 528 nm) and
converted to fluorescence polarization anisotropy which was plotted against
concentration of protein and fit to a one-site saturation binding model. SUPR-4B1W
was found to bind to GST-LC3A with a KD of 120 ± 19 nM while SUPR-4B bound to
GST-LC3A with a KD of 360 ± 83 nM (Figure 2C, D). This data supported our
prediction that the larger aromatic side-chain of tryptophan would engage more
strongly with the hydrophobic W-site binding pocket and increase the affinity of
SUPR4B1W for LC3A relative to SUPR4B. SUPR-4B1W was also found to bind to
GST-LC3B with a KD of 189 ± 40.1 while SUPR-4B bound to GST-LC3B with a KD of
392 ± 82.7 nM (Table 1). This indicates that selection against LC3A resulted in
ligands with similar affinities for the LC3B homolog which is unsurprising given the
83% residue identity and 90% residue similarity between the two proteins (Clustal
Omega alignment)
Binding affinity of both SUPR4B and SUPR4B1W for LC3A is significantly
enhanced by cyclization. Fluorescence polarization assays were carried out using
fluorescein-labeled linear SUPR4B and SUPR4B1W. Linear SUPR4B1W was found
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to bind to GST-LC3A with a KD > 375 nM while linear SUPR4B bound to GST-LC3A
with a KD > 690 nM. Linear SUPR4B1W was found to bind to GST-LC3B with a KD >
415 nM while linear SUPR4B bound to GST-LC3B with a KD >335 nM (Table 1).
These data indicate that cyclization provides at least 0.68 kcal/mol of binding energy
for

SUPR4B1W

when interacting with

LC3A likely

through reduction of

conformational entropy.
We also synthesized a version of SUPR4B1W in which the N-methyl-Lalanine at position 9 was replaced with L-alanine (SUPR4B1W8A) to determine the
effect of N-methylation on binding affinity.

Fluorescein-labeled SUPR-4B1W8A

bound to GST-LC3A with a KD of 105 ± 23.2 nM and GST-LC3B with a KD of 197 ±
52.1 nM. These affinities are very similar to those observed for SUPR4B1W and
indicate that incorporation of N-methylated amino acids does not positively
contribute to binding energy in the case of SUPR4B1W. A summary of binding
affinities obtained by fluorescence anisotropy is presented in Table 1.
LC3A KD (nM)

LC3B KD (nM)

SUPR4B1W Linear

> 375

> 415

SUPR4B1W Cyclic

120 ±19

189 ± 40.1

SUPR4B Linear

> 690

> 335

SUPR4B Cyclic

360 ± 83

392 ± 82.7

SUPR4B1W 8A Linear

> 1125

> 1250

SUPR4B1W8A Cyclic

105 ± 23.2

197 ± 52.1

Table 1 Binding affinities of SUPR peptides for LC3A/B by fluorescence polarization anisotropy
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SUPR Peptides Attenuate Atg4b-mediated cleavage of LC3
Atg4 is a cysteine protease that plays a critical role in the regulation of
autophagy through post-translational modification of LC3 homologs. Following
translation, Atg4 binds to LC3 via a LIM and cleaves the protein at the C-terminus to
expose a glycine residue which is lipidated with phosphatidylethanolamine (PE) prior
to membrane insertion. We hypothesized that if our SUPR peptides bound to the
Atg4 LIM-recognizing site on LC3, Atg4 binding and proteolytic cleavage would be
inhibited. LC3A bearing a C-terminal 7-amino-3-methylcoumarin moiety (LC3-AMC)
was pre-incubated with increasing concentrations of SUPR-4B, SUPR-4B1W, or a
scrambled version of either SUPR peptide. Since AMC is only fluorescent when free
in solution (λEx = 380 nm, λEm = 460 nm), cleavage of LC3 by Atg4 can be monitored
by increase in fluorescence at 460 nm. Atg4B (220 pM) was added to each
combination of LC3-AMC (120 nM) and SUPR peptide (0-100 µM) and fluorescence
emission was monitored for 40 minutes (Figure 2E). SUPR-4B inhibits Atg4B
cleavage of LC3-AMC with an apparent Ki > 100 µM while SUPR-4B1W inhibits
cleavage with apparent Ki ~ 35 µM. Neither scrambled peptide had any inhibitory
effect on Atg4B cleavage of LC3-AMC indicating that inhibition is sequencedependent. These results suggest that the SUPR peptides occupy the PPI hot spot
of LC3 and prevent formation of the Atg4:LC3 complex leading to inhibition of Cterminal proteolysis.
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Protease stability is dependent on cyclization and N-methyl incorporation
Peptides

are

highly

susceptible to proteolysis in
human

serum

and

this

feature has compromised the
translation of many peptides
into therapeutic compounds.
SUPR

mRNA

attempts

to

display

mitigate

drawback

this

through

macrocyclization
incorporation

of

and
N-methyl

amino acids which have been
shown to increase biological
half-lives

of

peptides

by

orders of magnitude (11).
Figure 3. Cyclization and N-methyl-L-alanine dramatically improve the
protease stability of SUPR4B1W. Analytical HPLC experiments show
that SUPR4B1W has a half-life in proteinase-K of~110 min (red line).
Without cyclization, linear SUPR4B1W has a half-life of 57 min, a nearly 2fold reduction (black line). N-L-methyl alanine plays a crucial role in
mediating protease resistance; substitution of L-alanine reduces the
protease half-life of the SUPR peptide to 6 min (blue line).

We

evaluated

the

protease stability of both
cyclic

and

linear

SUPR4B1W and as well as a variant where the N-methyl alanine residues is
replaced with alanine (SUPR4B1W8A). SUPR peptides were incubated for
increasing time with agarose-immobilized proteinase-K and subjected to analysis by
HPLC. SUPR4B1W was found to have a half-life in proteinase-K of 110 minutes,
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while the linearized version of the peptide was found to have a half-life of 57 minutes
(Figure 3). Removing the N-methyl-L-alanine dramatically increased susceptibility to
proteolysis; SUPR-4B1W8A was completely degraded within 60 minutes of
incubation with proteinase-k (half-life ~ 6 min). Based on these data, it appears that
N-methyl-L-alanine is a major driver of protease stability, as substitution with Lalanine completely abrogates resistance to proteinase-K degradation. Previous
SUPR mRNA display selections suggest that while incorporation of a single Nmethyl

amino

improvements

acid

moderately

improves

protease

resistance,

dramatic

in

protease stability (i.e.
order

of

magnitude)

are driven by multiple
N-methyl

residues

(11).

Indeed,

SUPR4B1W
incorporates two Nmethylated residues:
the

N-methyl-L-

Figure 5: SUPR4B1W Selectivity for LC3 Homologs. A) Crystal structure of
LC3 (5CX3146) showing the extent of residue conservation between LC3A,
LC3B, LC3C, GABARAP1, GABARA2, and Atg8. The W and L sub-sites are
highly conserved (circled in yellow). B) SUPR4B1W was immobilized on
neutravidin-acrylamide an incubated with [35S]-labeled LC3 homologs (LC3A,
B, and C along with GABARAP L1 and L2, Atg8 (the yeast ortholog of LC3) and
ubiquitin.
SUPR4B1W showed modest selectivity for LC3A and LC3B
compared with all other homologs and orthologs. No binding to ubiquitin was
observed.

alanine incorporated at position 8 and the proline at position 2. When considered
alongside the fluorescence polarization binding data, we can conclude that
incorporation of N-methyl-L-alanine was primarily driven by selection for protease
resistance, not selection for binding affinity.
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SUPR4B1W Selectivity for LC3 Homologs
Fluorescence polarization assays showed that SUPR-4B1W binds to LC3B
with an affinity similar to that of the selection target, LC3A. This is not entirely
unsurprising, as LC3A and LC3B share a high degree of sequence similarity,
particularly in the regions that define the protein-binding hot spot of each protein
(Figure 4A). We sought to determine whether SUPR4B1W, with its non-canonical
LIM, exhibits binding for other Atg8 mammalian orthologues or if binding was
specific for LC3A/LC3B. Open reading frames (ORFs) for LC3A, LC3B, LC3C,
GABARAP1, GABARAP2, Atg8, and Ubiquitin were transcribed into mRNA in vitro
and translated in vitro in the presence of [35S]-Methionine. SUPR4B1W was
biotinylated and immobilized on neutravidin-acrylamide resin and the radiolabeled
translation products were incubated with the resin. SUPR4B1W showed the highest
binding to LC3A followed closely by LC3B (Figure 4B), an observation in line with
our fluorescence anisotropy binding data. Moderate binding was also observed for
both isoforms of GABARAP as well as Atg8 (the yeast ortholog of LC3).

We

observed virtually no binding by LC3C, which can be explained by LC3C’s strong
preference for the LVV motif which is not found in SUPR4B1W(98). SUPR4B1W
showed no affinity for ubiquitin suggesting that the peptide binds to the LC3 hot spot
(defined by the W and L sub-sites) rather than the core ubiquitin fold.
Autophagy-related proteins that contain canonical LIMs often show affinity for
multiple isoforms of LC3 as well as isoforms of GABARAP, though affinity for each
isoform varies (98,146). There also exists a GABARAP Interacting Motif (GIM)—
(W/F)-(V/I)-X-V—which confers high selectivity for GABARAP proteins(133). Given
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its small size and non-canonical LIM, the isoform selectivity of SUPR4B1W is very
much in line with previously described linear LIM peptides.
SUPR4B1W is internalized into cells and co-localizes with punctate LC3 after
starvation
Before assessing its potential as a therapeutic inhibitor of autophagy, we
sought to validate the uptake of SUPR4B1W in human cell lines. We utilized coppercatalyzed click chemistry to conjugate the rhodamine derivative ROX-azide to
SUPR4B1W via the side chain of a C-terminal propargylglycine residue. HeLa cells
stably

expressing

eGFP-LC3B

were

grown

in

media

supplemented

with

SUPR4B1W-ROX (500 nM) for 24 hours. After 24 hours, cells were starved for 2
hours to induce autophagy prior to confocal microscopy imaging. Induction of
autophagy in this cell line results in a diffuse to punctate GFP staining pattern
reflecting transition of diffuse cytosolic LC3-GFP to autophagosomes. SUPR4B1WROX is taken up by both unstarved (Figure 5A) and starved (Figure 5B) HeLa-

Figure 6: SUPR4B1W co-localizes with LC3 in starved HeLa cells. SUPR4B1W-ROX was incubated with
HeLa cells expressing GFP-LC3 (green) in normal media (A) or starvation media (B) and visualized by confocal
fluorescence microscopy. After starvation, the EGFP-LC3 transitions from diffuse to punctate staining indicating
induction of autophagy. Significant overlap (yellow) of red and green puncta in starved cells indicates colocalization of LC3 and SUPR4B1W inside the cell. C) M1 and M2 co-localization coefficients were calculated
for three fields of starved and unstarved cells. The M2 coefficient (co-localization green signal with red signal)
increases after starvation. Scale bars represent XX µm.
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eGFP-LC3 cells, and in both cases displayed a punctate pattern suggesting an
endocytototic/pinocytotic mechanism of uptake (147). To quantify the extent of
colocalization between SUPR4B1W-ROX and GFP-LC3 puncta we calculated
Manders’ M1 and M2 colocalization coefficients for three fields of both starved and
unstarved cells (Figure 5C). The M1 coefficient gives the percentage of pixels in the
red channel (SUPR4B1W-ROX) that overlap with pixels in the green channel (eGFPLC3). The M2 coefficient gives the percentage of pixels in the green channel that
overlap pixels in the red channel. Starvation increases the M2 coefficient suggesting
an increased co-localization of LC3 puncta with SUPR4B1W-ROX after starvationinduced autophagy.

These data support cell uptake of SUPR4B1W and co-

localization with intracellular LC3.
SUPR peptides sensitize resistant cell lines to cisplatin in vitro.
One of the overarching goals of this project was to produce cyclic peptide
autophagy inhibitors that re-sensitized tumors to frontline chemotherapeutics.
Previous reports have shown that induction of autophagy is correlated with cisplatin
resistance in many human ovarian cancer cell lines including SKOv3, OVCAR8,
Hey, CAOv3, and OVCA420. Cisplatin activates extracellular signal-regulated kinase
(ERK) and promotes autophagy induction (89,148).

Inhibition of MAPK/ERK

signaling blocks autophagy induction and enhances cisplatin-induced apoptosis.
This suggests that targeting cisplatin-induced autophagy may be a viable strategy
for overcoming chemotherapy resistance in ovarian cancer.
To determine the utility of SUPR4B1W in this context, two platinum-resistant
epithelial ovarian cancer cell lines—OVCAR8 and HEY—were subjected to
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treatment with combinations of cisplatin and SUPR peptide for 48 hours before
cellular viability was evaluated by MTT assay (Figure 6A, B). In both OVCAR8 and
Hey, chloroquinine and cyclic SUPR4B1W significantly reduced cell viability in the
absence

of

cisplatin
whereas
linear
SUPR4B1W
did

not

(Tukey’s
HSD,
0.05).

p

<

Both

chloroquinine
and

cyclic

SUPR4B1W
reduced

cell

viability more
effectively in
the presence of
cisplatin in both
cell lines (p <
0.0001).
OVCAR8

In

Figure 7: SUPR4B1W sensitizes ovarian cancer cells to cisplatin and results in p62
accumulation and LC3-II/LC3-I perturbation. Treatment of OVCAR8 (A) and HEY (B)
ovarian cancer cells with SUPR4B1W and cisplatin significantly reduces cell viability after
48 h relative to cisplatin alone. A linearized version of SUPR4B1W showed no significant
effect on viability in the presence or absence of cisplatin. Incubation of cisplatin-treated
OVCAR8 cells (C) and Hey cells (D) with SUPR4B1W resulted in accumulation of p62 and
an increase in the LC3II/LC3I ratio indicating inhibition of autophagy while a scrambled
version of SUPR4B1W showed no effect. SUPR4B only showed perturbation of the
LC3II/LC3I ratio in Hey cells and did not cause accumulation of p62 in either cell line.

cells,

68

cisplatin and the cyclic SUPR peptide interacted synergistically to decrease cell
viability more than either cisplatin alone (p < 0.001) or chloroquine combined with
cisplatin (p = 0.0002). Treatment with scrambled SUPR4B1W resulted in no change
in viability compared to untreated. A linearized version of SUPR4B1W showed no
significant effects on viability alone or in conjunction with cisplatin (Tukey’s HSD, p >
0.05). These data suggest that viability changes are not the result of bulk uptake of
non-specific peptide into cells, but rather a specific interaction mediated by
SUPR4B1W. Enhancement of cisplatin efficacy was also seen in other ovarian cell
lines (SKOV3, OVCAR5), triple-negative breast cancer cell lines (MDA-MB-231),
and pancreatic cancer cell lines (Mia-PaCa-2, Panc1). These data suggest that
cyclic SUPR4B1W, rather than a linearized or scrambled version, inhibits autophagy
in cancer cell lines and sensitizes them to cisplatin-mediated cytotoxicity.
Western blots of treated cells show that combining cisplatin with both
SUPR4B1W leads to a dramatic accumulation of lipidated LC3-II and p62 in both
OVCAR8 and HEY cell lines (Figure 6C, D). Comparatively, the combination of CQ
and cisplatin induces an accumulation of p62 and a dramatic reduction of cytosolic
LC3-I and LC3-II. Cells undergoing autophagy typically show decreased levels of
p62 as the protein is degraded in the lysosome following autolysosome fusion, and
accumulation of p62 indicates disruption of autophagic flux(100). Taken together,
increased p62 and LC3 levels provides a strong indication that SUPR4B1W inhibits
cisplatin-induced autophagy in cell culture. Treatment with a scrambled version of
SUPR4B1W showed no significant effects on p62 accumulation or LC3 lipidation
indicating that this effect is sequence-dependent. Notably, SUPR4B showed some
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effect on the LC3II/LC3I ratio in
Hey cells but not in OVCAR8.
SUPR4B showed no effect on p62
accumulation in either cell line
which

is

consistent

with

its

reduced LC3 affinity relative to
SUPR4B1W.
SUPR4B1W sensitizes OVCAR8
tumors to carboplatin in nude mice
Given the encouraging cell-based
data, we next sought to determine
if

SUPR4B1W

could

sensitize

tumors to carboplatin treatment in
an

orthotopic

Cisplatin

mouse

resistance

in

model.
ovarian

cancer is frequently observed in
recurrent, metastatic nodules that
appear

throughout

the

peritoneum (149). Intraperitoneal
injection

of

OVCAR8

cells

provides a suitable model for
recurrent,

resistant

Figure 8: SUPR 4B1W Inhibits Tumor Growth in vivo. A)
OVCAR8 cells were injected into the peritoneum of nude mice (n
= 8 per group) followed by i.p. treatment with carboplatin (25
mg/kg, 3 times per week), SUPR4B1W (10 mg/kg, 3 times per
week), or a combination of the two for 3 weeks. SUPR4B1W +
carboplatin dramatically reduced tumor mass relative to
carboplatin alone while SUPR4B1W alone had no effect. B) The
same therapeutic trial was carried out for 4 weeks with the
introduction of a scrambled version of SUPR4B1W.
The
combination of SUPR4B1W and carboplatin almost completely
eliminated intraperitoneal growth in 4 weeks while the
combination of carboplatin and a scrambled peptide showed no
improvement relative to carboplatin alone.

metastatic

disease in nude mice. When injected, OVCAR8 forms tumor nodules throughout the
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abdominal peritoneum and gastrointestinal tract. To determine the effect of
SUPR4B1W on tumor nodule formation, nude mice were IP-injected with 2 million
OVCAR8 cells and subsequently treated 3 times weekly with combinations of
carboplatin, SUPR4B1W, and chloroquine. At 3 weeks, the mice were sacrificed, the
tumors were dissected, and total tumor mass for each treatment condition was
evaluated (Figure 7A). Treatment with SUPR4B1W alone had no impact on tumor
development (Tukey’s HSD, p = 0.9827), but combining SUPR4B1W with
carboplatin resulted in a significant reduction in total tumor mass compared to
treatment with carboplatin alone (Tukey’s HSD, p = 0. 0032). This experiment was
repeated, extending the treatment period to 4 weeks and treatment with a scrambled
version of SUPR4B1W (Figure 7B). At 4 weeks, combined SUPR4B1W and
carboplatin treatment again had a strong effect on tumor growth with 70% of mice in
the SUPR4B1W+carboplatin group showing no observable tumor development.
Combining scrambled SUPR4B1W with carboplatin resulted in no difference in total
tumor mass compared to treatment with carboplatin alone (Tukey’s HSD, p =
0.9911).

These results provide a strong indication that SUPR4B1W selectively

inhibits autophagy in tumors and may provide a potent lead compound for future
therapeutic development.
Conclusions
We have employed SUPR peptide mRNA Display to design SUPR4B1W, a
potent, cell-permeable inhibitor of the LC3 protein. This macrocyclic peptide shows
mid-nanomolar affinity for LC3A and LC3B and selectivity for LC3A/B over other
Atg8 orthologs. Binding studies revealed the cyclization contributes modestly, but
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significantly, to the binding energetics of SUPR4B1W while the non-proteogenic Nmethylalanine is dispensable for affinity. In contrast, the N-methyl alanine residue is
absolutely essential for protease resistance while the contribution of cyclization to
stability is modest. These results suggest that the incorporation of N-methyl amino
acids is driven primarily by selection for protease resistance rather than target
affinity.
Fluorophore-tagged SUPR4B1W is readily taken up in HeLa cells and
displays a punctate staining pattern consistent with endocytosis or pinocytosis.
While heavily N-methylated cyclic peptides have previously been shown to cross the
cell membrane by diffusion (139), this mechanism of uptake would presumably have
resulted in a diffuse staining pattern, particularly in unstarved cells where LC3 is
distributed evenly throughout the cytosol. Given the relatively low fraction of Nmethylation (25% of the randomized region) and the presence of an aliphatic
macrocyclic bridge, we propose that the mechanism of uptake may be similar to that
of stapled peptides which are also believed to transit the cell membrane by
endocytosis and/or pinocytosis(150). While it has also been proposed that stapled
peptides enter the cell following membrane disruption(151,152), we found no
evidence of this mechanism by microscopy or by the appearance of non-specific
toxicity in cell culture and animal models. Future studies will address the effect of Nmethylation, charge, and hydrophobicity on the mechanism and extent of SUPR
peptide cell penetration.
SUPR4B1W sensitizes multiple cell lines to cisplatin treatment and results in
accumulation of p62 and significant perturbation of the LC3II/LC3I ratio.

These
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results strongly suggest that SUPR4B1W disrupts the PPIs of LC3 inside the cell
and inhibits autophagosome maturation. Accumulation of LC3II, the lipidated form of
LC3, may indicate that SUPR4B1W inhibits Atg4 binding and subsequent proteolytic
recycling of LC3II – a conclusion supported by in vitro data showing inhibition of
Atg4B proteolysis by SUPR4B1W.

Inhibition of LC3II recycling could arrest

autophagic flux by attenuating the rate of formation of new autophagosomes,
although this mechanism of action remains to be proven experimentally.
The combination of SUPR4B1W and carboplatin results in almost complete
inhibition of tumor outgrowth in vivo suggesting that this compound could be
administered in an adjuvant setting to enhance the efficacy of platinum-based
therapies or to prevent the outgrowth of platinum-resistant disease. Although the
combined effect of SUPR4B1W and cisplatin was also observed in cell culture, the
effect size was significantly lower relative to the in vivo models. This divergence
may be the result of context.

It has previously been shown that induction of

autophagy in ovarian cancer cell lines results in a strikingly different survival
phenotype than autophagy induction in the corresponding animal models (80). This
was attributed to the effects of a relatively nutrient-poor tumor microenvironment
compared to the nutrient-rich conditions found in cell culture.

Alternatively the

striking effect of SUPR peptide/carboplatin combinations in vivo may be the result of
both chemotherapeutic effects and enhancement of the innate immune system.
Although athymic nude mice were used to generate the orthotopic models, these
mice still retain a functional innate immune system(153,154).

Previous work in

breast cancer (155) and renal cell carcinoma (RCC) (156) models has shown that
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autophagy inhibition sensitizes these tumors to natural killer (NK)-mediated cell
killing by preventing degradation of secreted granzyme. Inhibition of autophagy in
macrophages has also been shown to alter polarization from M2 to M1 which could
facilitate a pro-inflammatory, anti-tumoral response (157). Future studies will be
carried out to deconvolute the effect of SUPR peptide-mediated autophagy inhibition
on tumor viability, drug resistance, and the immune response.
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CHAPTER THREE
THE ARHI MODEL OF INDUCIBLE AUTOPHAGY IN OVARIAN CANCER
This chapter is based in part upon sections of Ornelas, A., McCullough, C.R., Lu, Z.
et al. Induction of autophagy by ARHI (DIRAS3) alters fundamental metabolic
pathways in ovarian cancer models. BMC Cancer 16, 824 (2016).
https://doi.org/10.1186/s12885-016-2850-8
Introduction
Aplasia Ras homolog member I (ARHI also known as DIRAS3) is an
imprinted tumor suppressor gene that is known to exhibit reduced or total loss of
expression in breast(158), lung (159), hepatocellular (160), and pancreatic (161)
carcinomas as well as greater than 60% of ovarian carcinomas (80,162). ARHI
encodes for a small 26 kDa GTPase that is known to have great >50% homology
with the various isoforms of RAS, a well-studied oncogene that frequently drives
runaway growth signaling in carcinomas (163). ARHI blocks homodimerization of
RAS and subsequent downstream growth signaling by forming heterodimers with
RAS (164). Additionally, ARHI has been shown to inhibit the AKT-PI3K-mTOR
pathway, the inhibition of which is a known initiator of autophagy. Re-expression of
ARHI in ovarian carcinoma provides an excellent model of inducible autophagy and
a powerful tool to study the impact of autophagy on tumor metabolism(80). Reexpression of ARHI under the control of doxycycline in the ovarian carcinoma cell
lines SKOv3 and OVCAR8 induces highly elevated levels of autophagic flux
resulting in non-aptoptotic cell death with 72 hours of induction. We sought to gain a
better understanding of the impact of ARHI-induced autophagy on metabolic
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dysfunction and discovered that ARHI-mediated autophagy induces significant
changes in mitochondrial membrane potential and generation of reactive oxygen
species (ROS), a potent cellular stressor. When autophagic SKOv3-ARHI and
OVCAR8-ARHI cell lines are treated with SUPR4B1W—a macrocyclic SUPR
peptide inhibitor of LC3 PPIs—cell death is no longer observed and cells return to a
normal viability phenotype at 72 hours post autophagy induction.
Materials and Methods
Cell Culture
ARHI-inducible SKOv3-ARHI ovarian cancer cells were maintained in
McCoy’s 5A medium supplemented with 10% tetracycline-free fetal bovine serum, 2
mM L-Glutamine, and 1% (v/v) penicillin-streptomycin. ARHI-inducible OVCAR8ARHI ovarian cancer cells were maintained in RPMI 1640 medium supplemented
with 10% tetracycline-free fetal bovine serum, 2 mM L-Glutamine, 1 mM NaPyruvate, and 1% (v/v) penicillin-streptomycin.
Uptake of Mitotracker Red FM by Fluorescence Microscopy
SKOv3-ARHI cells were seeded into 96 well plates and treated with 1µg/ml
Dox for 48 hours or grown untreated in complete media for 48 hours. Cells were
treated with 50 nM MitoTracker Red FM (Invitrogen) for 45 minutes in FBS free
media. Cells were then washed with 1x PBS (Hyclone) and immediately imaged by
fluorescence microscopy (λex = 581 nm, λem = 644 nm) using a Biotek Cytation5
Cell Imaging Multi-Mode Reader
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Uptake of TMRM and H2DCFDA by Flow Cytometry
SKOv3-ARHI cells were treated with 1 μg/ml Dox for 24 and 48 h or with 50
nM Rapamycin for 24 h. Cells were then incubated with 20 nM tetramethyl
rhodamine methyl ester (TMRM) in FBS-free media for 45 min, washed twice with
phosphate buffered saline, and resuspended in FBS-free media. The mean
fluorescence intensity for 10,000 cells was obtained by flow cytometry.
SKOv3-ARHI and SKOv3 (parental) cells were treated with Dox (1 μg/ml) for
12, 24 and 48 h. In a separate experiment SKOv3-ARHI cells were treated with Dox
(1 μg/ml) for 48 h with and without BPTES (1 μM). The cells were then washed and
stained with 5 μM H2DCFDA and analyzed by flow cytometry to obtain the mean
fluorescence intensity. Triplicate samples were used for each experimental condition
and analysis of the results was performed in GraphPad. The statistical significance
was determined by unpaired, two-tailed t-test in GraphPad (*, p < 0.05; **, p < 0.01)
TOM20 Staining by Flow Cytometry
SKOv3-ARHI cells were seeded into a 75 cm2 flask and allowed to reach
confluence. Cells were treated with 1 μg/ mL of Doxycycline for different time points
as previously discussed. After treatment, cells were trypsinized and harvested at
500xg for 10 min. Cells were then fixed in 3 % formaldehyde and permeabilized with
0.1 % Triton X100. Cells were then counted, aliquoted and incubated in 2 μg of
TOM20 antibody (Santa Cruz Biotechnology) for 40 min. Cells were then washed
and incubated in F(ab’) 2- Goat anti Rabbit IgH (H + L) Secondary Antibody, Alexa
Fluor® 488 conjugate (Thermo Scientific).
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Effect of Autophagy inhibitors on Cellular Viability following ARHI induction
SKOv3-ARHI and OVCAR8-ARHI cells were seeded into 96-well plates at a
density of 5,000 cells per well and treated with Dox for 24, 48, or 72 hours or grown
for 72 hours without Dox treatment. Treatment media was replaced daily. Cells
underwent simultaneous treatment with SUPR4B1W (50 µM), SUPR4B1W scramble
(50 µM), Chloroquine (5 µM), or were untreated. Treated cells were give 50 µM
SUPR4B1W in full media for 24, 48, or 72 hours. After 72 hours, cells were washed
with 1X PBS and viability was measured by MTT assay. The statistical significance
of difference in viability was determined by unpaired, two-tailed t-test in GraphPad (*,
p < 0.05; **, p < 0.01)
Results and Discussion
ARHI expression modulates mitochondrial membrane potential & intracellular
oxidative state
Staining of SKOv3-ARHI cells with Mitotracker dye following induction of
ARHI revealed a signficant decrease in dye uptake suggesting a loss of
mitochondrial membrane potential, potentially induced by depletion of mitochondria
through autophagic flux (Figure 1A). To quantitate this effect, SKOv3-ARHI cells
were treated with Dox followed by the Nernstian fluorescent probe TMRM and
analyzed by flow cytomtery. Uptake of cationic Nernstian probes like TMRM is
dependent on mitochondrial membrane potential, and the intensity of fluorescence
generated by the probe can be used as a semi-quantitative measure of
mitochondrial membrane potential. Treatment with Dox resulted in a decrease in
TMRM uptake which was most pronounced at 24 h post-induction (Figure 1B). In
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contrast, treatment with rapamycin had no effect on TMRM uptake. In order to
determine if low TMRM uptake was being driven by low mitochondiral membrane
potential or by a decrease in the number of mitochondria, SKOv3-ARHI cells were
fixed and permeabilized following induction with Dox for 12, 24, and 48 h. The cells
were then stained for the presence of the TOM20 receptor of the mitochondrial outer
membrane preprotein translocase and analyzed by flow cytometry. Significantly
lower Tom20 signal was observed after 12 h of Dox induction suggesting a decrease
in the mitochondrial mass following ARHI induction (Figure 1C). We also sought to
determine the effect of ARHI induction on the intracellular oxidative state using the
oxygen-sensitive dye H2DCFDA. Induction of ARHI was found to increase
H2DCFDA uptake by flow cytometry by almost 3-fold after 48 h (Figure 1D). This
result is in good agreement with results of previous work. In contrast, parental
SKOv3 cells showed no statistically significant change in H2DCFDA following
treatement with Dox indicating that changes in intracellular redox state were the
result of ARHI expression. Finally, we measured H2DCFDA uptake following ARHI
induction and BPTES treatment for 48 h (Figure 1E). BPTES is a selective inhibitor
of Glutaminase GLS1, a critical component in glutamine metabolism. We found that
BPTES treatment resulted in decreased H2DCFDA uptake in Dox-induced SKOv3
cells while BPTES treatment alone resulted in no statistically significant change.

79

Figure 9 ARHI Expression alters Mitochondrial Membrane Potential and ROS in SKOv3-ARHI. A) SKOv3-ARHI
cells were treated with and without Dox followed by staining with Mitotracker Red FM and visualized by
fluorescence microscopy at 24 h. B) SKOv3-ARHI cells were treated with Dox or Rapamcyin for the indicated
times followed by tetramethyl rhodamine methyl ester (TMRM). The mean fluorescence intensity (MFI) was
obtained by flow cytometry. C) SKOv3-ARHI cells were treated with Dox for 48 h, followed by fixation in 3 %
paraformaldehyde and permeabilization with 0.1 % Triton X-100. Cells were then stained with TOM20 antibody
(Santa Cruz Biotechnology) and a secondary goat Anti-rabbit IgG conjugated to AF488® and analyzed by flow
cytometry D) SKOv3 (parental) and SKOv3-ARHI cells were treated with Dox for the indicated times followed by
H2DCFDA and analyzed by flow cytometry. The resulting MFI values were normalized to the Dox- value in
either the parental or ARHI-transfected cell line. E) SKOv3-ARHI cells were treated with Dox for 48 h with and
without BPTES (1 uM) followed by staining with H2DCFDA and analysis by flow cytometry
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Treatment with SUPR4B1W restores viability following ARHI expression
Induction of ARHI expression in SKOv3-ARHI and OVCAR8-ARHI by addition
of Dox (1µg/mL) to culture media results in extreme autophagic flux that causes a
marked reduction in cellular viability within 48 hours. Previous work suggests that
this cell death occurs through apoptotic and non-apoptotic pathways due to a
depletion of essential cellular proteins and organelles by autophagy. We sought to
determine whether inhibition of autophagy following ARHI expression could restore
cellular viability. As described in Chapter 2, SUPR41BW is a macrocyclic, proteaseresistant peptide that has high affinity and selectivity for LC3. SUPR4B1W disrupts
protein-protein interactions (PPIs) necessary for early autophagosome maturation,
and has shown evidence of enhancing the effect of platinum-based
chemotherapeutics in models of metastatic, resistant ovarian carcinoma. SKOv3ARHI and OVCAR8-ARHI were induced for autophagy for 24, 48, or 72 hours and
split into groups that received concurrent treatment with SUPR4B1W (50 µM),
SUPR4B1W scramble (50 µM), Chloroquine (CQ) (5 µM), or no treatment. After 72
hours, cellular viability was measured by MTT assay. Cells that did not undergo
autophagy induction showed no change in viability (Figured 2A & 2B) when treated
with SUPR4B1W or its amino acid sequence scrambled counterpart suggesting that
treatment with SUPR peptide alone is non-toxic. Treatment with CQ in the absence
of ARHI induction resulted in a significant reduction in cellular viability in OVCAR8ARHI cells after 72 hours of treatment (Figure 2B). CQ is a lysosomtropic agent that
non-specifically accumulates in acidic vesicles where it raises vesicular pH
inactivating lysosomal hydrolases. Both SKOv3-ARHI and OVCAR8-ARHI cells
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demonstrate a return to normal levels of cellular viability at 72 hours post-induction
when combined with SUPR4B1W treatment (Figure 2C & 2D). Combined treatment
with scrambled SUPR4B1W or CQ shows no statistically significant restoration of
viability. Combined treatment of CQ with DOX induction results in reduced cellular
viability in OVCAR8-ARHI compared to induction alone, which is expected as
OVCAR8-ARHI cells appear to be sensitive to prolonged CQ treatment even under
normal growth conditions. While both CQ and SUPR4B1W appear to inhibit
autophagy, their mechanisms of action differ dramatically. CQ acts late in the
development of autophagosomes and in fact does not directly impact the autophagy
machinery at all. CQ only acts after the autophagosome has fused with the
lysosome to prevent final degradation of the autophagosome’s contents. Those
contents—such as essential organelles like mitochondria—are still sequestered
inside vesicles where they cannot carry out their normal cellular functions. Since
ARHI expression results in cell death due to depletion of essential cytosolic
machinery by autophagy, it stands to reason that CQ would not restore cellular
viability since it cannot prevent the sequestration of organelles and proteins. As
demonstrated in Chapter 2, SUPR4B1W disrupts LC3 PPIs necessary for
autophagosome maturation both in vitro and in cells. We therefore hypothesize that
SUPR4B1W impacts early autophagosome formation and maturation preventing
essential cytosolic machinery from becoming isolated in functional vesicles.
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Figure 10 MTT assays of cellular viability in the ARHI expression model. A) SKOv3-ARHI and B) OVCAR8-ARHI
cell lines show no impact on viability from SUPR peptide treatment in the absence of ARHI expression. CQ
results in a significant reduction in cellular viability in OVCAR8-ARHI after 72 hours of treatment. C) SKOv3-ARHI
and D) OVCAR8-ARHI cells show restoration of normal viability patterns after 72 hours of ARHI induction
combined with SUPR4B1W treatment. SUPR4B1W scramble and CQ show no restoration of viability at 72 hours
compared to induced cells that did not receive treatment

Conclusion
Inducible ARHI expression in ovarian carcinoma is a unique and powerful
model that has provided numerous insights into both tumor development and altered
cancer metabolism. This study has shown that ARHI expression fundamentally
alters mitochondrial function in ovarian cell lines. We observed both reduced TMRM
fluorescence and TOM20 signal by flow cytometry following ARHI induction,
suggesting a decrease in cytosolic mitochondrial mass. Additionally, we observed
that the generation of ROS increases following ARHI expression. Both reduced
mitochondrial mass in the cytosol and increased ROS production could be explained
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if ARHI-induced autophagy is resulting in the sequestration of mitochondria in
autophagic vesicles and autolysomes where they subsequently become
dysfunctional. We hypothesize that this leads to increased ROS burden.
Interestingly, while both ARHI expression and inhibition of glutamine metabolism
through BPTES treatment result in increased ROS production, combined Dox and
BPTES treatment resulted in less ROS production than Dox treatment alone. Further
studies should focus on why inhibition of glutamine metabolism reduces ROS
production in the context of ARHI-induced autophagy.
It has previously been established that ARHI expression leads to significant
cell death within 48 hours, likely due to depletion of essential cellular machinery
through highly increased autophagic flux. We demonstrated that treatment with
SUPR4B1W concurrent with ARHI expression is able to abrogate this loss in cellular
viability, possibly by disrupting the early formation and maturation of
autophagosomes through the inhibition of LC3 PPIs. Autophagy inhibitors like CQ
that disrupt end-stage degradation of autolysosome contents do not restore viability,
suggesting that they act too late in the autophagic process to rescue viability.
Further studies will focus on examining the impact of SUPR4B1W on early
autophagosome development through the use of electron microscopy which is able
to directly visualize autophagosomes and their contents. Additionally, further studies
will examine the impact of SUPR4B1W on in vivo models of ARHI expression where
it is known that ARHI expression results in transition to dormancy rather than cell
death and increased autophagic flux is thought to be essential in mediating survival
during dormancy.
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CHAPTER FOUR
MULTI-WAVELENGTH PHOTOACOUSTIC VISUALIZATION OF
HIGH INTENSITY FOCUSED ULTRASOUND LESIONS
This chapter is based upon Gray, J. P., Dana, N., Dextraze, K. L., Maier, F.,
Emelianov, S., & Bouchard, R. R. (2016). Multi-Wavelength Photoacoustic
Visualization of High Intensity Focused Ultrasound Lesions. Ultrasonic
Imaging, 38(1), 96–112. Copyright © 2016 SAGE Publications
https://doi.org/10.1177/0161734615593747
Introduction
High intensity focused ultrasound
High intensity focused ultrasound (HIFU) is a minimally invasive technique
that has developed significantly over the last two decades for the treatment of
benign and malignant conditions in soft tissues (165,166). HIFU treatments use
ultrasound transducers with highly controlled beams to instantly achieve destructive
temperatures at their focus. This technique has been used to treat targets that may
be several centimeters below the skin surface, while preserving healthy tissue since
hyperthermal therapy tends to occur at the focus of the beam (166). HIFU is of
clinical interest for several conditions, including atrial fibrillation of cardiac tissue
(167,168), central nervous system disorders of the brain (169), treatment of both
benign and malignant solid tumors through thermal ablation (166), and enhanced
drug delivery at treatment sites (170). In the United States, HIFU has been indicated
for clinical treatment of uterine fibroids and malignant bone metastases (171).
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Image guidance is employed during HIFU for treatment planning, tissue
temperature, and assessment of tissue damage during and after treatment (i.e.
estimating treatment margins) (166). Real-time image guidance has accommodated
adaptive ablation planning, leading to increased efficacy of HIFU treatments and
improved precision in estimating treatment margins (166). Imaging guidance for
hyperthermal therapy has been provided by magnetic resonance (MRI) imaging,
computed tomography (CT), and ultrasound (US), all of which have been able to
elucidate anatomical structures and heating-probe location (172). Several of these
techniques have demonstrated the capability to monitor tissue temperature changes,
yet only MRI is used as a standard-of-care technique for image guidance during
clinical treatments (173,174).

Photoacoustic imaging
Photoacoustic (PA) imaging is a relatively novel technique that is gaining
attention due to its feasibility of implementation as a point-of-care imaging solution,
its molecular sensitivity, and its ready compatibility with existing US technology
(175). PA imaging can be achieved through extracorporeal or interstitial application
of near-infrared (NIR) laser pulses, which are absorbed by endogenous
chromophores or exogenous contrast agents (176,177). Due to the “optical window,”
in which optical absorption by water, fat, and blood decreases dramatically in the
NIR region (650-1100 nm), imaging depths of several centimeters can be achieved
in soft tissues (178). Photon energy absorbed by chromophores is converted into
mechanical energy through a rapid thermal expansion, which results in the
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generation of an acoustic transient that propagates through soft tissue and may be
detected by a standard US transducer at the tissue surface (175,176). Detected
signals can then be used to estimate a map of optical absorption with sub-millimeter
spatial resolution. Since PA signals are detected using an ultrasonic transducer, PA
images can be co-registered with US images (175). These photoacoustic-ultrasonic
(PAUS) images allow for the presentation of anatomical information alongside
estimated optical absorption, and thus molecular composition, of the tissue.
The amplitude of PA pressure waves, 𝑝𝑝0 (𝒓𝒓, 𝑇𝑇, 𝜆𝜆), generated as a result of

optical absorption by chromophores in tissue, are dependent on the speed of sound
in tissue (𝑣𝑣𝑠𝑠 (𝑇𝑇) [cm s-1]), a temperature-dependent volume expansion coefficient

(𝛽𝛽(𝑇𝑇) [K-1]), the isobaric heat capacity in tissue (𝐶𝐶𝑝𝑝 (𝑇𝑇) [J kg-1 K-1]), the optical
absorption coefficient of the tissue (𝜇𝜇𝑎𝑎𝑎𝑎𝑎𝑎 (𝒓𝒓, 𝜆𝜆) [cm-1]), and the optical fluence (Φ(𝒓𝒓, 𝜆𝜆)

[J cm-2]) as (175–177)

𝑝𝑝0 (𝑟𝑟, 𝑇𝑇, 𝜆𝜆) = �

𝛽𝛽(𝑇𝑇)𝜈𝜈𝑠𝑠2 (𝑇𝑇)
� 𝜇𝜇𝑎𝑎𝑎𝑎𝑎𝑎 (𝑟𝑟, 𝜆𝜆)Φ(𝑟𝑟, 𝜆𝜆).
𝐶𝐶𝑝𝑝 (𝑇𝑇)

Eq. 1

Contrast in PA images arises from variations in the optical absorption
coefficient, which depends on both the concentration of chromophores in tissue and
the wavelength of the laser source. Due to the wavelength dependence of the optical
absorption coefficient, multi-wavelength photoacoustic imaging can be performed by
varying the wavelength of the laser through the entire NIR region in order to estimate
the optical absorption properties of the tissue (175,179). Varying the location of the
PAUS transducer or using a 2D array and obtaining PA signals at several
wavelengths allows for the generation of a multi-wavelength 3D PAUS volume.
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Additionally, the temperature dependence of pressure wave generation may allow
for real-time monitoring and characterization of temperature change during ablation
(180–183).

Current image-guidance methods
Image guidance techniques greatly improve the outcome of HIFU treatments
by allowing physicians to more accurately and completely estimate treatment
margins, yet existing imaging modalities are not entirely satisfactory for treatment
guidance (172,184,185). Currently, image guidance of HIFU treatments is performed
using several standard imaging modalities. Traditional pulse-echo B-mode US
provides excellent anatomical information and can provide short-term identification
of hyperechoic regions of tissue corresponding to microbubble formation at the site
of the HIFU focus; however, it cannot provide quantification of lesion extent (186).
Elastography can be used to assess and characterize induced lesions, but can be
difficult to implement in vivo and provide a significant number of false-positives
(187). Magnetic resonance imaging (MRI) allows for excellent identification of
treatment targets, treatment planning, and real-time tracking of relative temperature
changes at the site of ablation through MRI thermography (173,174,188), but it is
limited by the high cost and equipment incompatibility imposed by high magnetic
field strengths. PA imaging is a promising modality for image guidance of HIFU
therapies because of its ready compatibility with existing technology and capability to
monitor target and healthy tissue during ablation with sub-millimeter spatial
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resolution. This level of spatial resolution in fact exceeds the spatial resolution of
existing temperature MRI guidance techniques (1-2 mm) (166,189).

HIFU guidance with PA imaging
PA imaging provides several unique qualities that make it promising as an
alternative to existing image-guidance techniques for HIFU. PA imaging is capable
of both thermography and spectroscopy (180,190,191), allowing for real-time
assessment of temperature changes and tissue state. In practice, conventional US
techniques such as Doppler imaging or microbubble-contrast perfusion assessment
can also be applied concurrently with PA imaging to assess nearby critical
structures, such as vessels (175).
Previous studies of HIFU ablations in vitro and in vivo using PA imaging have
shown that PA imaging is capable of providing image contrast in the ablation region
(192–197). This change in contrast at the ablation site may be attributed to a change
in the concentration of chromophores in the tissue as a result of heating (198).
However, single-wavelength methods typically fail to provide enough information to
reliably quantify the precise position and dimensions of HIFU lesions. Studies using
radio-frequency ablation have shown that multi-wavelength PA imaging is capable of
detecting changes in the concentration of chromophores—specifically in the
concentration of deoxy-hemoglobin (Hb)—following thermal ablation and that these
multi-wavelength methods allow PA imaging to identify an optical absorption
spectrum specific to ablated tissue and distinct from the typical Hb spectrum
(191,194). In this study, we use the previously described technique (191,194) in an
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in vitro environment following HIFU and water-bath ablation of cardiac and liver
tissue samples. 2D and 3D multi-wavelength PA data of ablated tissue samples is
then correlated to these two absorption spectra to create Tissue Characterization
Maps (TCM), which are used to quantitate lesion size for comparison to stained
gross pathology. Additionally, we examine the temperature dependence of the PA
signal as tissue samples are heated in a PBS bath.

Figure 1. Photographs of experimental equipment. A) LabFUS 2.5-MHz small-animal HIFU
system. B) Close-up view of eight-element, 2.5-MHz HIFU transducer. C) Vevo LAZR 2100
combined PAUS imaging system. Red arrow indicates motorized platform for elevation
scanning during 3D imaging.
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Methods
Sample preparation and ablation procedure
Imaging samples were acquired from fresh porcine cardiac and liver tissues
(Animal Technologies Inc., Tyler, TX) within 24 hours of sacrifice and were never
frozen. Excised tissues from one liver and two hearts were used to make three liver
samples and three cardiac samples, each approximately 30x30x20 mm3 in size.
Each specimen was embedded into an agar phantom for HIFU sonication. The HIFU
transducer was acoustically coupled to the agar phantoms using ultrasound gel and
samples were each sonicated for 120 seconds at power settings between 22 and 30
watts using a LabFUS 2.5-MHz small-animal HIFU system (Image Guided Therapy
Inc., Paris, France). Photographs of the HIFU system, HIFU transducer, and imaging
system are presented in Figure 1. Following ablation, tissue specimens were
removed from their agar phantoms, and the uppermost 1.5 – 2 mm of tissue surface
was removed in order to expose ablation lesions to allow for tissue-sample
photography and later co-registration with imaging data.
Additionally, fresh bovine liver tissues (Animal Technologies Inc., Tyler, TX)
were acquired within 24 hours of sacrifice and never frozen. Two samples were
excised from one liver and submerged in normal PBS in an imaging chamber
containing a heat exchanger. The goal of this experiment was to monitor the tissue
PA signal as a function of bath temperature. The tissue sample was located in the
center of the copper tubing coil, which comprised the heat exchanger, to generate
an approximately isotropic temperature field. Bath temperature was measured via
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thermocouple at a location a few millimeters from the upper surface of the tissue
imaging plane.

Imaging setup
Following the aforementioned ablation procedure, specimens were anchored
in a thin layer of gelatin and submerged in normal phosphate buffered saline (PBS)
to achieve acoustic coupling between the tissue sample and the PAUS transducer.
PAUS imaging was performed using a Vevo LAZR 2100 imaging system equipped
with a 21-MHz US transducer coupled to a pulsed Nd:YAG laser capable of
irradiating from 670-970 nm (FUJIFILM VisualSonics Inc., Toronto, Canada). In each
sample, a single-wavelength 3D PAUS scan was performed over the extent of the
tissue sample in order to identify a single plane containing the ablation lesion. The
location of the lesion was chosen by selecting an area in the 3D PAUS scan
exhibiting a hyperechoic US signal and high PA contrast. After identification of the
lesion, a 2D comprehensive multi-wavelength PA scan was performed on this plane
using wavelengths ranging from 680-970 nm in 3-nm steps. A multi-wavelength 3D
PAUS scan was then performed on each tissue over a volume including the ablation
lesion using five wavelengths in the NIR region (740, 750, 760, 780, 900 nm),
corresponding to a distinct feature in the Hb absorption spectrum (199), and
averaging eight frames for each wavelength and location.
For the bath-heated samples, multi-wavelength PA imaging was done using
five wavelengths in the NIR region (740, 750, 760, 770, 780 nm), corresponding to
the same Hb spectral feature. First, a baseline multi-wavelength PA acquisition was
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performed. The bath-heat exchanger was then activated, and the tissue bath
temperature rapidly rose to approximately 60 °C. PA imaging at all wavelengths was
conducted at one-minute intervals for the first 30 minutes, then at five-minute
intervals thereafter, up to 60 minutes. Bath temperature was measured at each
imaging time-point. Immediately post-imaging, the tissue sample was removed from
the water bath and bisected at the imaging plane. Photographs were taken of the
sample prior to heating, as well as at the point of bisection post-heating.

Staining procedure
Following imaging, samples were stained using triphenyl tetrazolium chloride
(TTC) salts for registration and comparison of gross pathology to PAUS data
(Sigma-Aldrich Corp., St Louis, MO). TTC is a redox indicator of metabolic activity:
the white stain accumulates in cells and is oxidized to a deep red color by a variety
of molecules associated with metabolic activity (200,201). Tissue in the ablation
region has undergone necrosis and should become white/gray in color, while
metabolically active healthy tissue outside the ablation region will become a deep
red. Staining solutions were prepared by dissolving 0.1 mg/ml TTC in normal PBS.
Tissue samples were submerged in staining solution and incubated at 37° C for 20
minutes with constant stirring. After staining, tissue samples were patted dry and
photographed. Bath-heated tissue samples were not stained as the tissue was
clearly coagulated throughout the entire tissue volume.
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2D multi-wavelength PA analysis
The comprehensive 2D multi-wavelength scans were analyzed to assess
whether HIFU treatment results in a change in the PA spectra of tissue. Regions of
interest (ROI) were selected in areas showing high PA contrast and areas showing
low PA contrast, corresponding to areas of ablated and non-ablated tissue,
respectively. The mean PA signal inside each ROI was calculated for each
wavelength scanned and plotted to display the absorption spectra for ablated (liver
and cardiac, respectively) and non-ablated tissue (Figure 2).

Figure 2 Results of 2D comprehensive multi-wavelength PA imaging. A) Overlay of singlewavelength PA data at 710 nm on matched US image. High PA contrast and US hyperechogenicity
exhibited in area where lesion is expected. B) Plot of mean PA signal in each ROI indicated at each
wavelength. Mean PA spectrum in areas outside lesion exhibit the characteristic peak of Hb around
760 nm; peak not seen in area of high PA contrast where lesion is expected.

Creation of tissue characterization maps
Tissue characterization maps (TCMs) were generated using a correlationbased algorithm. Reference absorption spectra for ablated and Hb absorbers were
obtained from the comprehensive multi-wavelength PA data (liver or cardiac, as
appropriate) using previously described methods (191). The filtered PA data were
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compared to two reference spectra (i.e. Hb correlation and a distinct ablated
correlation for each tissue type), resulting in two 3D datasets of Pearson correlation
coefficients. These two 3D correlation datasets (i.e. Hb correlation coefficients and
ablated correlation coefficients) were then processed with a simple thresholding
algorithm. Correlation thresholds of 0.6 were used for both Hb and ablated reference
spectra. PA voxels were then classified based on the respective thresholds and
correlation coefficients. Voxels that correlated strongly (i.e. displayed correlation
coefficients above the threshold) to only one reference spectra were classified
accordingly (i.e. class 2 for ablated; class 1 for Hb). Voxels that correlated strongly
to both were classified according to their greatest correlation coefficient. Voxels that
correlated strongly to neither reference spectra were classified as 0 (no correlation).
Thus, a trinary 3D TCM was constructed for each PA dataset and compared to
photographed gross pathology. For the bath-treated tissue samples, an equivalent
process was employed, save that a correlation threshold of 0.65 was used. A 2D
TCM was generated at each time point, and the 2D multi-wavelength PA signal was
examined as a function of time (i.e. thermal exposure).

Image registration and characterization of ablation size
HIFU 3D TCM data were co-registered with top-view photographs of stained
gross pathology by manual registration based on corresponding visual landmarks.
Top-view C-scan TCMs were obtained by taking the mode along the depth axis for
each voxel at the surface of the TCM volume. Mode calculations were performed
from a depth 0.184 mm (corresponding to five voxels, which tended to avoid
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subsurface fluence artifacts) below the surface of the volume to a depth 1.29 mm
(corresponding to 35 voxels) below the surface. Borders between areas of ablation
and non-ablation were manually segmented in matched TCMs and pathology
photographs by three experts, generating three segmentations for each TCM or
pathology photograph. The segmentations for each TCM or photograph were
analyzed automatically using MATLAB. Pixel-wise lesion area was calculated from
each expert-segmentation of corresponding TCM data and gross pathology
photographs. The mean and standard deviation of lesion areas from the expert
segmentations were calculated and subsequently converted to physical dimensions
(mm2). Percent area agreement between gross pathology and TCMs was calculated
for each tissue sample as
% 𝐀𝐀𝐀𝐀𝐀𝐀𝐀𝐀 𝐀𝐀𝐀𝐀𝐀𝐀𝐀𝐀𝐀𝐀𝐀𝐀𝐀𝐀𝐀𝐀𝐀𝐀
= 𝟏𝟏 −

|𝐒𝐒𝐒𝐒𝐒𝐒𝐒𝐒𝐒𝐒𝐒𝐒𝐒𝐒𝐒𝐒𝐒𝐒 𝐈𝐈𝐈𝐈𝐈𝐈𝐈𝐈𝐈𝐈 𝐀𝐀𝐀𝐀𝐀𝐀𝐀𝐀 − 𝐒𝐒𝐒𝐒𝐒𝐒𝐒𝐒𝐒𝐒𝐒𝐒𝐒𝐒𝐒𝐒𝐒𝐒 𝐏𝐏𝐏𝐏𝐏𝐏𝐡𝐡𝐡𝐡𝐡𝐡𝐡𝐡𝐡𝐡𝐡𝐡 𝐀𝐀𝐀𝐀𝐀𝐀𝐀𝐀|
𝐒𝐒𝐒𝐒𝐒𝐒𝐒𝐒𝐒𝐒𝐒𝐒𝐒𝐒𝐒𝐒𝐒𝐒 𝐏𝐏𝐏𝐏𝐏𝐏𝐏𝐏𝐏𝐏𝐏𝐏𝐏𝐏𝐏𝐏𝐏𝐏 𝐀𝐀𝐀𝐀𝐀𝐀𝐀𝐀

Eq.
2

An SNR analysis was done, comparing SNR up to 8 mm tissue depth, while
varying the number of averages. A 0.21x0.18 mm2 sliding kernel was used,
analyzing signal along a depth line located in the center of the ROI shown in Figure
5A. Additionally, a noise image was acquired (degassed water, no laser irradiation)
to assess PA image noise at the equivalent depth. Up to 64 averages were used.
Analysis was done on beam-formed image data, using the following equation
����
𝑷𝑷𝑷𝑷
𝐒𝐒𝐒𝐒𝐒𝐒 = 𝟏𝟏𝟏𝟏 ⋅ 𝐥𝐥𝐥𝐥𝐠𝐠 𝟏𝟏𝟏𝟏 �
�,
𝝈𝝈𝒏𝒏𝒏𝒏𝒏𝒏𝒏𝒏𝒏𝒏

Eq.
3
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where ����
𝑷𝑷𝑷𝑷 and 𝝈𝝈𝒏𝒏𝒏𝒏𝒏𝒏𝒏𝒏𝒏𝒏 denote the ROI mean PA signal and noise standard deviation,

respectively. The SNR threshold was empirically determined by analyzing the depth,
and thus corresponding SNR, at which the TCM loses continuity (i.e. the point at
which the gaps/inconsistencies in the solid TCM regions become as large as or
greater than the spatial averaging kernel used).

Results
2D multi-wavelength PA analysis
Figure 2 displays the results of 2D multi-wavelength PA imaging performed in
liver tissue. Figure 2A shows an overlay of the single-wavelength PA signal at 710
nm on its matched US image. ROIs shown in Figure 2A represent the area
averaged at each wavelength to generate the reference spectra from ablated and
non-ablated tissue; these spectra are shown in Figure 2B. We expect the dominant
absorber to be Hb in this wavelength region as the ex vivo tissue samples should be
oxygen-depleted (178). Non-ablated tissue displays an absorption spectrum that
agrees well with that of Hb (191) as the characteristic local maximum in the
absorption spectrum around 760 nm is readily apparent. The absorption spectrum in
the ROI corresponding to ablated tissue decreases monotonically with increasing
optical wavelength and does not display the characteristic 760-nm local maximum of
the Hb absorption spectrum, indicating a likely change in the concentration of Hb
absorbers due to hyperthermia.
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Lesion area statistics
TCMs were created by correlating to wavelengths in the region between 740 and
780 nm; the region where ablated tissue and Hb absorption spectra are most
distinct. Tissue characterization was achieved at depths up to 3 mm below the
surface of the tissue, while gross pathology indicated that lesions extend 5-7 mm in
depth. Examples of 3D TCM volumes overlaid on matching US volumes for liver and
cardiac tissues are shown in Figure 3.
Results of area calculations performed on manually segmented lesions in
both TCMs and gross pathology photographs can be found in Table 1; a
representative sample image can be found in Figure 4. In TCM volumes, we
observed areas of tissue bordering the areas of strong ablation correlation that
correlated poorly to both ablated and non-ablated absorption spectra. These areas
were segmented in addition to the area that was primarily classified as the lesion
and was also compared to gross pathology.
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Liver #1

Liver #2

Liver #3

Cardiac #1

Cardiac
#2

Cardiac
#3

Pathology Area
(mm2)

16.9±1.8

35.3±3.7

22.2±2.0

11.4±1.0

10.3±0.1

3.5±0.2

Combined Ablated
Core and NonCorrelation Region
area (mm2)

15.7±1.9

28.1±0.2

22.2±0.1

11.5±0.4

7.21±0.2

3.2±0.1

% Area
Agreement
Combined Ablated
Core and NonCorrelation Region

93.2%

79.8%

99.9%

99.1%

70.0%

91.7%

Ablated Core Area

8.53±0.1

25.6±0.1

20.0±0.1

11.6±0.6

7.2±0.2

2.1±0.2

% Area
Agreement
Ablated Core

50.6%

72.5%

90.2%

98.3%

70.1%

61.2%

Table 1 Results of area calculations performed on manually segmented lesions in both
TCMs and gross pathology photographs.

For the bath-heated samples, Figure 5A–E shows a 2D TCM overlaid on coregistered B-Mode US images for five time points, with a rectangular square
identifying an ROI for spectral analysis. At baseline (Fig. 5A) strong correlation to
Hb is observed to approximately 4 mm in depth across the entire width of the tissue
sample. The depth of this correlation decreases to about 2 mm by 15 minutes (Fig.
5B). By 30 minutes, a thin layer correlating to ablated tissue can be identified at the
tissue surface (Fig. 5C). At 45 minutes, 1 – 2 mm of ablated tissue is identified at the
surface, with only sporadic Hb is identified beneath the surface, and this trend
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continues at 60 minutes (Fig. 5E). Figure 5F shows a surface plot of the mean PA
signal of the ROI, normalized to baseline, as a function of wavelength and time. The
PA signal rapidly increases for the first 5 minutes after heating onset, but still
maintains the Hb spectral shape (local maximum at 760 nm). Amplitude decreases
slightly, but spectral shape is maintained until approximately 30 minutes, at which
point the spectra begins to flatten, correlating more strongly to the ablated reference
spectra thereafter (as shown by the surface color). Figure 5G allows for better
comparison of the spectra at prominent time points. Note that at 5 minutes after
heating onset (bath temperature of 52 °C) a PA signal increase of approximately
80% from baseline can been seen across all wavelengths. The signal decreases
slightly, but remains relatively constant at roughly 50% above baseline until about 30
minutes after heating onset. At 30 minutes, we can see the PA spectrum flattening
out, and by 45 and 60 minutes, we observe a monotonically decreasing spectrum
that strongly resembles the ablated reference spectrum for liver.
Analysis of TCMs against the SNR results suggests that an SNR of 10 dB is
generally sufficient for reliable tissue characterization using this method. By
increasing averages, we found SNR using this method can be improved
approximately proportional to �# averages,

allowing accurate TCMs at greater

depths in tissue, though at the cost of increased imaging time.
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Figure 3 Renderings of 3D TCM volumes overlaid matching 3D US volumes. A) Full liver sample 3D
volume rendering and B) cut-away view of 2D frame in the interior of the lesion of the same liver
volume. C) Full cardiac sample 3D volume rendering and D) cut-away view of 2D frame in the
interior of the lesion of same cardiac volume.

Discussion
In this initial study, we demonstrate that multi-wavelength PA imaging can
provide estimates of lesion extent with gross pathology area agreement greater than
79% in liver and greater than 70% in cardiac tissue. As has been shown previously
(193,197,202) and demonstrated in this study (Figure 2), high PA signal contrast in
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the ablated lesion center can be obtained using a single laser wavelength. However,
PA imaging data from a single wavelength tends not to be sufficient to completely
characterize the extent of
the ablation lesion. While
single-wavelength

PA

imaging may be useful to
perform a quick 3D scan
and

obtain

a

rough

identification of the lesion
center,

multi-wavelength

TCMs provide significantly
more information about the
boundaries and extent of
ablation lesions, as shown
by comparing figures 2A
and

3B

and

5A–E.

Focusing

on

the

wavelengths

where

the

Figure 4 Comparison of gross pathology and TCM data for one liver
tissue sample. A) Photographed stained gross pathology. Red box
indicates area of tissue displayed by 2D TCM data. B) Zoomed in
photograph of stained gross pathology. Manual segmentation of gross
pathology overlaid in green. C) C-scan 2D TCM plane reconstructed
from TCM volume for manual segmentation. Blue indicates Hb
correlation, Red indicates ablated spectrum correlation, black indicates
correlation to neither spectra.

absorption spectra of ablated and non-ablated tissue display different features, multiwavelength TCMs were able to identify HIFU ablation lesions in ex vivo cardiac and
liver tissue and obtain area agreement with gross pathology photographs in excess
of 70% and with sub-millimeter spatial resolution. TCMs compared well with
manually segmented gross pathology photographs (minimum 70% area agreement),
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demonstrating
multi-wavelength
PA imaging as a
potential tool for
HIFU

lesion

identification

and

quantification.

Despite our
success

in

the

identification

and

characterization of
HIFU

ablation

lesions in cardiac
and liver tissues,
limitations in PA

Figure 5. Comparison of TCMs (same color-coding as previously stated) and spectra
for sample subjected to PBS-bath thermal treatment: (A) to (E) TCMs overlaid on coregistered US B-mode image for time-points 0 (baseline), 15, 30, 45, and 60 minutes
of thermal treatment, respectively. White rectangular box denotes a 1 × 0.5 mm2 ROI
selected for analysis, maintained at constant depth from tissue surface; (F) surface
plot of mean PA signal in ROI (normalized to baseline), as a function of wavelength
and time. Surface color-map represents mean TCM color value across ROI at each
time-point; (G) PA-signal spectra from F for time-points 0, 5, 15, 30, 45, and 60
minutes (time-points at 0, 15, 30, 45, and 60 minutes correspond to images A to E,
respectively). TCM = tissue characterization map; PBS = phosphate buffered saline;
US = ultrasound; PA = photoacoustic; ROI = regions of interest.

imaging and our
experimental
setup

prevent

ideal
characterization of

lesion dimensions. Imaging artifacts immediately at the surface of the tissue were
observed and are believed to be the result of subsurface photon fluence and
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refractive index discontinuities between the surface of the tissue and the PBS used
to couple the tissue to the ultrasound transducer. In our study, these artifacts were
mitigated when creating 2D TCM images of the top-view plane by using a depth
0.184 mm below the tissue surface as the starting point for reconstruction of the Cscan projected views.
PA based TCMs also underestimated lesion depth in this experiment. Depth
of PA imaging is limited by scattering of photons which increases the likelihood of
absorption by chromophores at shallower depths in the tissue. In this experiment,
imaging depths were limited to no more than 3 mm below the surface of the tissue,
yet HIFU lesions extended 5-7 mm in depth. Several techniques could be employed
in order to increase the penetration depth of imaging, including increased photon
fluence and increased frame averaging to improve the signal-to-noise ratio at depth,
as discussed below. Interstitial delivery of light by laser fibers also allows for
significantly deeper light delivery to provide image guidance of treatments on deeplying tissues, such as the liver and kidneys (203). By employing these methods, it
should be possible to extend imaging depth beyond 3 mm in ex vivo experiments.
Additionally, penetration depth could possibly be improved in in vivo experiments
due to the fact that tissues will be highly oxygenated. Optical absorption by
oxygenated hemoglobin is roughly an order of magnitude lower in the NIR spectrum
than that of Hb (179). This reduction in optical absorption may allow increased
optical penetration depth while maintaining energy, but it may require re-optimizing
imaging wavelengths to maintain contrast between ablated and native oxygenated
tissue.
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A noteworthy effect observed in this experiment was the appearance of a ring
of tissue surrounding the area correlating to ablated tissue in TCMs that did not
correlate well to either the obtained ablated tissue spectrum or the standard Hb
spectrum. This effect was observed in both liver and cardiac tissue in our study and
has been reported in previous studies (191). In cardiac tissues, the area of noncorrelation was not always observed. An example of this effect is seen in Figure 4C,
where an area of non-correlated tissue (i.e. black) borders the upper area correlating
highly to ablated tissue (i.e. red) at the core of the lesion. The segmentation region
containing the region of ablation-correlated (red) and non-correlated (e.g. also
including the black region extending from 4-6 mm in elevation in Fig. 4C) tissue
showed better agreement with segmented ablation regions in gross pathology
photographs than the segmentations of the ablation-correlated region alone.
Regions of ablation correlation alone tended to underestimate the area extent of
lesions when compared to gross pathology segmentations. The change in the PA
spectrum in ablated tissue likely results from hyperthermia-induced changes in the
Hb chromophore. It is possible that incomplete conversion of Hb occurs at the edge
of the ablation region due to reduced increase in local temperature as compared to
the core of the lesion, resulting in an absorption spectrum that did not correlate well
to either Hb or the lesion core.
The capacity of PA imaging to assess temperature has been previously
demonstrated by examining changes in PA amplitude (180,183) . By applying similar
techniques, we were able to track the relative temperature rise in the bath-heated
tissue sample during the first several minutes. As shown in Figure 5F, the PA
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amplitude then decreases slightly after five minutes. We suspect this is primarily a
result of changes in surface fluence. As can be seen in the B-Mode US images in
Figure 5, the tissue swells initially (B and C), before contracting partially (D and E).
This initial tissue swelling is likely the result of increased osmotic pressure in the
bath, following temperature increase. The swelling is likely to affect and the surface
fluence, due to a change in separation between the tissue and light emission source.
The tissue contraction observed in Figure 5D and 5E is likely due coagulation of
ECM proteins, which concurs with the observed strong correlation of the PA signal to
the ablated reference spectrum (red region in figures). These results highlight the
potential complementary nature of PA thermography and multi-wavelength analysis.
Tissue coagulation may also explain the decrease in PA amplitude after 30 minutes,
as increased optical scattering following coagulation will reduce fluence, and thus
PA signal, at greater depths. While these factors confound PA thermography in this
experiment, these issues may not be as prevalent in clinical applications for several
reasons. First, tissue hyperthermal therapy typically occurs on the order of several
seconds to a few minutes and is typically much more spatially localized, which may
reduce large scale tissue swelling or edema. Lastly, if an optical scattering increase
within an ROI correlates to a change in the observed PA spectra, as suggested by
this study, it may serve as a partial endpoint for hyperthermal therapy, rather than a
mitigating factor to image guidance. Furthermore, if changes in optical fluence and
absorption can be accounted for (perhaps by collecting some backscattered light for
diffuse reflectance assessment (204)), PA thermography may be able to quantify
thermal dose, comparable to what is currently done using MRI thermography.
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The SNR analysis suggests that roughly 10 dB SNR is necessary for reliable
TCM analysis. Our particular system showed that, with 64 averages, the SNR up to
5 mm can be improved to allow for reliable TCM analysis. While increased averaging
may be prohibitive in some clinical applications, such as cardiac imaging, this
analysis suggests a baseline to predict TCM accuracy as a function of depth for a
given application and imaging system.

Future work
Development of in vivo imaging solutions will be necessary to apply PA
imaging clinically for guidance of HIFU treatments. Although development of an in
vivo system for combined HIFU therapy and PAUS imaging will not be a trivial task,
building upon previous work by Cui et al. (193,195,202) and Prost et al. (205) may
improve single-device integration, which allows straightforward co-registration of
HIFU ablation space with PA and US imaging spaces. This would overcome a
significant hurdle for clinical translation.
Real-time image guidance remains a currently unrealized goal for developing
PA imaging systems. While this study used a laser source with a pulse repetition
frequency (20 Hz) that limited acquisition to near-real-time imaging (five singlewavelength frames per second, without averaging), commercial laser systems
operating at kilohertz pulse repetition frequencies are readily available at select
wavelengths, albeit sometimes with lower pulse energies. These systems may allow
PA imaging, with proper wavelength selection, to achieve complete real-time image
guidance exceeding 30 frames per second (191).
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Corroboration of these results in an in vivo model is necessary in order to
confirm that the findings reported here are relevant to further clinical application.
One recent study (192) has reported inconclusive findings, showing that while most
single-wavelength ex vivo studies reported positive PA contrast in the ablation
lesion, it is possible to observe negative contrast in ablation lesions in vivo. One
proposed explanation is that variations in thermal deposition between in vivo and ex
vivo models may lead to a different distribution of chromophores between the two
environments. As our method relies upon correlation to multiple laser wavelengths, it
may be possible to identify a difference in the chromophores present in the ablated
regions of in vivo and ex vivo models. While the data in this study suggests Hb is
present in significant quantities before ablation and is significantly reduced following
ablation, it is not clear which chromophore(s) is generating PA signal in the ablated
region. Previous work has suggested that increased temperatures during thermal
therapy may give rise to a variety of hemoglobin derivatives, which may account for
the observed contrast between normal and ablated tissue (206–208). While
production of hemoglobin derivatives is often cited as a potential source of contrast
in ablated tissues, to our knowledge no study has shown definitively that the
proposed derivatives are produced in significant concentrations in tissue. Studies of
the thermal unfolding and aggregation process of hemoglobin using 2D infrared
spectroscopy have shown that thermal degradation is a complex, multi-step process
that is irreversible once local tissues reach a certain temperature threshold: initial
destabilizations in the structure of hemoglobin occur at low temperatures between
30-44° C; complete thermal unfolding occurs between 44-54° C; and irreversible
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aggregation of the denatured protein occurs at temperatures above 54° C (209).
This complex, three-stage denaturation process involves several potentially
irreversible conformation changes in the structure of hemoglobin. Given the
dependence of protein absorption on the 3D structure of the protein, these
irreversible, temperature-dependent structural changes in hemoglobin may explain
the observed elimination of the 760-nm peak in the Hb spectrum in ablated tissue.
Partial unfolding of Hb may yield a range of different absorption spectra in ablated
tissues rather than a single absorption spectrum corresponding to a single
chromophore. This range of unfolding states could explain the observed correlation
discrepancies at the edges of tissue lesions and could be developed to benchmark
levels of partial tissue coagulation. In future studies, it would be useful to submit
samples of ablated and non-ablated tissues to hemopathological and chemical
assays in order to identify with confidence which chromophores are present and in
what concentration before and after ablation.
PA-based temperature monitoring must also account for changes in optical
absorption and fluence. A previous study (210) monitored the PA signal ratio at two
different wavelengths during tissue heating, verifying that PA signal variations occur
consistently across wavelengths until the tissue undergoes a change of state (i.e.
thermal coagulation), as we observed. By analyzing complementary PA-signal
amplitude and multi-wavelength techniques used herein with more applicable
hyperthermia models (RF- and HIFU-hyperthermal therapy using in vivo models), we
can better evaluate and improve their utility, which is paramount to implementing
real-time imaging guidance for thermal treatment.

109

Conclusion
We have demonstrated the feasibility of using multi-wavelength PA imaging to
create tissue characterization volumes that allow the differentiation of HIFU-induced
tissue ablation lesions from non-ablated tissue and to estimate the treatment
margins of tissue ablations in 2D planes in ex vivo cardiac and liver tissue samples
following a HIFU ablation. Multi-wavelength PA imaging demonstrates that HIFUinduced hyperthermia results in changes in the Hb absorption spectrum that can be
leveraged for PA-based segmentation. Multi-wavelength TCMs were used to
successfully identify lesion size with a greater accuracy than single-wavelength
methods. Multi-wavelength TCMs agreed with gold-standard stained pathology
images (70% area agreement) and were able to successfully assess lesion margins
with a spatial resolution comparable to existing temperature MRI techniques.
Additionally, we demonstrated the complementary nature of PA thermography and
multi-wavelength TCMs. Further in vivo experiments concurrent with treatment must
be performed to assess PA signal changes in living tissues. These results suggest
that multi-wavelength PA imaging and PA thermography present a promising
modality for guiding hyperthermia therapies that depend on precise knowledge of
temperature and lesion extent in order to preserve critical structures.
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CHAPTER FIVE
CONCLUSION
In this dissertation we have discussed the issue of disease-generating
intracellular protein-protein interactions (PPIs) and the challenges they pose for
researchers. Traditional small molecule drug design has narrowly focused on a
particular area of chemical space to produce “druglike” molecules that passively
diffuse through the cell membrane to inhibit proteins by occupying localized
hydrophobic binding pockets on the surfaces of proteins, primarily the active sites of
enzymes. These targets represent only a small portion of disease-generating targets
however, and drug-like small molecules lack the size to interrupt PPIs when those
interactions occur through the interface of surfaces that measure hundreds or even
thousands of square Angstroms. Biologics have addressed this problem, at least in
part, by virtue of the fact that monoclonal antibodies—which typically mass ~150
kDa)—have the requisite size to bind to massive protein surface areas and in fact
are often larger than their targets. Production of monoclonal antibodies is often
prohibitively expensive however, and the main asset of antibodies—their size—is an
Achilles heel as it prevents them from accessing intracellular compartments.
Peptides occupy a potentially useful region of chemical space between small
molecules and biologics. At a length of ~5-20 amino acids, therapeutically-releveant
peptides have masses in the range 500-2500 Da and surface areas >400 Å2.
Molecules in this range have sufficient size to disrupt many PPIs, yet peptides have
historically been largely ignored as therapeutic candidates due to issues of stability
and cell permeability of linear peptides. In recent decades, technological
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developments have made great strides in resolving these issues. Lessons learned
from cell-penetrating peptides and naturally cell permeable cyclic peptides like
Cyclosporine A have made it clear that elimination of hydrogen bond donors in the
peptide backbone and stabilization of the peptide structure through cyclization are
key properties inherent to stable, cell-permeable peptides. Backbone stabilization—
through macrocyclization or stapling—and incorporation of N-methylation of
backbone amides are now common design choices that produce serum stable
peptides often capable of accessing the cytosol. Directed evolution technologies like
mRNA display are able to efficiently screen massive libraries of peptides—far larger
by orders of magnitude than any small molecule screen—to produce molecules that
bind targets and disrupt PPIs with affinity and selectivity comparable to antibodies.
Technological advancements in mRNA display technology, notably SUPR peptide
mRNA display, incorporate N-methylation, macrocyclization, and protease screens
produce serum stable peptides that retain superior binding properties. Excitingly,
many of the features that impart protease resistance are now known to facilitate cell
permeability, opening the door to the deployment of SUPR peptide mRNA display as
a design tool to develop new compounds that target intracellular PPIs.
In this dissertation, we have described SUPR mRNA display selections
against LC3, a small ubiquitin-like protein that plays a crucial role in autophagy. The
lead candidate from these selections, SUPR4B1W, bound to LC3 with a midnanomolar affinity and showed specificity for the LC3A and LC3B isoforms of LC3.
SUPR4B1W disrupts interactions between LC3 and the autophagy related protein
Atg4b in vitro and has a biological half-life of approximately 2 hours in the presence
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of the highly active protease, Proteinase K. Evidence of autophagy inhibition was
observed in two different models of ovarian cancer treated with SUPR4B1W.
SUPR4B1W
rescued viability in
the DIRAS3 model
after 72 hours of
treatment while
chloroquine—a
non-specific antiautophagy
compound that
disables lysosomal
degradation—does
Figure1. 3D structure of SUPR4B1W. One of the conformational ensemble
structures reveals that Arg5 side chain forms multiple internal hydrogen bonds with
several other residues including the backbone carbonyl oxygens of Ala8, Lys10 and
Gly12. This may partially explain the enhanced stability of cell permeability of
SUPR4B1W.

not. These data,
along with
evidence that

SUPR4B1W inhibits Atg4B activity in vitro, suggest that SUPR4B1W may inhibit the
early autophagy machinery and frustrate autophagosome formation. In models of
autophagy-induced cisplatin resistance, treatment with SUPR4B1W re-sensitized
ovarian cancer cells to cisplatin causing a significant reduction in cellular viability
compared to treatment with cisplatin alone. Treatment with SUPR4B1W, in
combination with cisplatin, also effectively prevented outgrowth of tumor nodules in

114

nude mice four weeks after intraperitoneal injection with an ovarian carcinoma cell
line.
Until now, development of autophagy inhibitors has relied on the directed
evolution of naïve libraries. Future work on SUPR peptides targeting LC3 will focus
on rational design and optimization using predictive modeling of the structure of
SUPR4B1W to determine the mechanism of its interactions with LC3.
Our collaborators the
laboratory of Shuxing Zhang have
generated structural models of
potential conformers of
SUPR4B1W. Using this method,
the Zhang lab demonstrated that
the side-chain of Arg5 in
SUPR4B1W forms multiple
internal hydrogen bonds with
Figure 2: Preliminary computational models of SUPR4B1W
docked into the active sites of LC3. Green surface represents
hydrophobic areas on LC3, blue for electrostatic positive and
red for negative.

several other amino acids in the
peptide (Figure 1). These internal

hydrogen bonds may contribute strongly to both the stability and cell permeability of
SUPR4B1W.
To model SUPR peptide – LC3 interactions, the LC3A crystal structure
(PDB:5CX3) was imported into MOE software. Preliminary modeling based on the
initial preposition of SUPR4B1W in the binding pocket of LC3, indicates that the
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Pro3 facilitates formation of beta turn involving residues His4, Arg5, and Val6
(Figure 2). Such beta turn structure explains how SUPR4B1W can accommodate an
extra residue between the W-site and L-site binding residues as well as enhanced
affinity relative to peptides lacking proline at the third position. Moreover, this model
supports our hypothesis that the Trp2 side chain interacts with W site and the side
chain of Val6 interacts
with L site. Interestingly,
the imidazole side chain
of His4 stacks with the
side chain of His27 in
LC3, potentially
contributing to the biding
energy of the cyclic
Figure 3 preliminary modeling of SUPR4B1W linear predicts that without the
beta turn imposed by proline in the cyclic conformation, it is difficult for Val6
to associate with the L-site resulting in reduced affinity

peptide. Modeling of the
linearized version of

SUPR4B1W provides some insight into why cyclization improves binding (Figure 3).
Without the beta turn imposed by cyclization and Pro3, the linear peptide struggles
to accommodate the addition of a third spacer amino acid to the LIM and presents
Arg4 in the L-site rather than Val5. These observations provide structural evidence
to explain the higher affinity of cyclized SUPR4B1W relative to the linear version.
Modeling of the selected SUPR4B peptide (phenylalanine at position 2) predicts a
significantly weaker binding energy which we observe experimentally.
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In the future, we will carry out computational alanine scans to gain knowledge
about the impact of specific residues on the conformation of SUPR4B1W and its
interaction with LC3. By computationally mutating individual residues of SUPR4B1W
to alanine and docking the new structure into LC3, we can better understand the
impact of specific amino acid residues. This data will inform future medicinal
chemistry efforts to drive the affinity of SUPR4B1W into the low nanomolar regime.
Preliminary computational alanine scanning indicates that mutation of Trp2 or Val6
significantly reduces the affinity to LC3, a prediction that is entirely consistent with
our experimental data. Mutating Trp2 to Ala results in maximum affinity reduction
while mutating Val6 to Ala results in second highest reduction in affinity.
Interestingly, mutating Arg5 to Ala resulted in increase in affinity. The models show
that Arg5 does not interact with LC3 receptor and is instead involved in forming
multiple hydrogen bond interactions with backbone carbonyl oxygen atoms. We
speculate that replacing such Arg with Ala may contribute to increased affinity for
LC3 while decreasing its cell permeability through the disruption of the
intramolecular hydrogen bond network. Further modeling can help identify amino
acid substitutions that may convey improved properties such as binding affinity or
specificity for individual isoforms of LC3.
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